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ABSTRACT 42 
Background: Interleukin-23 (IL-23) is the key cytokine for generation of pathogenic 43 
IL-17-producing helper T (Th17) cells that critically contribute to autoimmune diseases. 44 
However, how IL-23 generates pathogenic Th17 cells remains to be elucidated.  45 
Objectives: To examine the involvement, molecular mechanisms and clinical 46 
implications of prostaglandin (PG) E2-EP2/EP4 signaling in induction of IL-23-driven 47 
pathogenic Th17 cells. 48 
Methods: The role of PGE2 in induction of pathogenic Th17 cells was investigated in 49 
mouse Th17 cells in culture in vitro and in IL-23-induced psoriasis mouse model in 50 
vivo. Clinical relevance of findings in mice was examined by gene expression profiling 51 
of IL-23 and PGE2-EP2/EP4 signaling in psoriatic skin from patients.  52 
Results: IL-23 induces ptgs2 encoding cyclooxygenase 2 in Th17 cells and produces 53 
PGE2, which acts back on PGE receptors EP2 and EP4 in these cells and enhances IL-54 
23-induced expression of an IL-23 receptor subunit gene, Il23r, by activating STAT3, 55 
CREB1 and NF-κB through cAMP-protein kinase A signaling. This PGE2 signaling 56 
also induces expression of various inflammation-related genes, which possibly function 57 
in Th17 cell-mediated pathology. Combined deletion of EP2 and EP4 selectively in T 58 
cells suppressed accumulation of IL-17A+ and IL-17A+IFN-γ+ pathogenic Th17 cells 59 
and abolished skin inflammation in IL-23-induced psoriasis mouse model. Analysis of 60 
human psoriatic skin biopsies shows positive correlation between PGE2 signaling and 61 
the IL-23/Th17 pathway.  62 
Conclusions: The T cell-intrinsic EP2/EP4 signaling is critical in IL-23-driven 63 
generation of pathogenic Th17 cells and consequent pathogenesis in the skin. 64 
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IL-23 triggers T cell-intrinsic PGE2-EP2/EP4 signaling that is critical in Th17 cell-66 
mediated immune pathogenesis.  67 
The PGE2-EP2/EP4 signaling functions synergistically with IL-23 and not only 68 
amplifies Il23r expression but also induces a unique pathogenic gene expression 69 
signature by activating STAT3, CREB1 and NF-κB. 70 
This PGE2 signaling can be a therapeutic target of Th17 cell-mediated diseases, because 71 
combined blockade of EP2 and EP4 suppresses IL-23-induced pathogenic Th17 cell 72 
generation and consequent psoriatic skin inflammation. 73 
 74 
Capsule Summary 75 
IL-23 mobilizes T cell-intrinsic PGE2-EP2/EP4 signaling, which is critical in IL-23-76 
induced pathogenic Th17 cell generation. Combined blockade of EP2 and EP4 77 
suppressed IL-23-induced skin inflammation, suggesting this pathway as potential 78 
therapeutic target of Th17-mediated diseases. 79 
 80 
Key words: psoriasis, pathogenic Th17 cells, IL-23R, prostaglandin E2, prostaglandin E 81 
receptor EP2, prostaglandin E receptor EP4, STAT3, CREB1, NF-κB     82 
         83 
Abbreviations used: 84 
Th1, helper T cell type 1 85 
Th2, helper T cell type 2 86 
Th17, helper T cell type 17 87 
Treg, regulatory T cell 88 
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COX, cyclooxygenase 90 
cAMP, cyclic adenosine monophosphate 91 
PKA, protein kinase A 92 
CREB, cAMP Responsive Element Binding Protein 93 
Epac, exchange factor directly activated by cAMP 94 
db-cAMP, dibutyryl cAMP 95 



































CD4+ T cells differentiate into Th1, Th2 and Th17 cells in response to specific cytokine 116 
milieu present in microenvironment of inflammation and mediate immune inflammatory 117 
responses in respective settings.1-4 Among these Th subsets, Th17 cells mediate 118 
inflammatory responses in many autoimmune diseases including multiple sclerosis, 119 
inflammatory bowel diseases such as Crohn’s disease, psoriasis and rheumatoid 120 
arthritis. The importance of Th17 cells in these processes was suggested first in animal 121 
models of these diseases including experimental autoimmune encephalomyelitis (EAE) 122 
and IL-23- or imiquimod-induced psoriasis model,5-9 and validated recently by clinical 123 
effectiveness of antibodies targeting to IL-23 in patients with psoriasis.10-14  124 
 Differentiation of Th17 cells from naïve CD4+ T cells is driven by the 125 
combined actions of interleukin-6 (IL-6) and transforming growth factor-β1 (TGF-126 
β1).15-19 However, differentiated Th17 cells have little capacity to induce autoimmune 127 
and inflammatory pathology.20 It should be noted that these Th17 cells exhibit plasticity 128 
and could transdifferentiate into other effector T cell types or even regulatory T cells 129 
under certain context such as inflammation or autoimmune disease.21-23 Accumulating 130 
evidences suggest that T cell intrinsic IL-23 signaling not only increases IL-17 131 
production of Th17 cells but also plays a crucial role in inducing and stabilizing their 132 
pathogenicity.20,24-27 It is known that IL-23 acts on IL-23 receptor composed of IL-23R 133 
and IL-12Rβ1, activates signal transducer and activator of transcription 3 (STAT3) and 134 
induces expression of Il23r, thus forming the self-amplification loop. The 135 
pathophysiological importance of this IL-23-IL-23 receptor signaling has been indicated 136 
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polymorphisms (SNPs) of genes involved in this pathway, e.g., IL23R, IL12B (p40), 138 
JAK2 and STAT3, and a wide range of IL-17-dependent autoimmune diseases.28-30  139 
 While it was shown that IL-23 signaling induces expression of Th17 140 
pathogenic signature genes through activation of STAT3,31,32 other transcription 141 
factor(s) besides STAT3 are also implicated for induction of pathogenic Th17 cells, 142 
because IL-6 that activates STAT3 similarly to IL-23 cannot induce IL-23R gene 143 
expression.32 The identity of additional transcriptional factor(s) and regulatory 144 
mechanisms are therefore important issues to be defined. Moreover, how IL-23 145 
cooperates with other inflammatory factors formed in disease microenvironment and 146 
how critical is such cooperation for pathogenic conversion of Th17 cells and overall 147 
pathology remain largely obscure. Clarification of these points could provide a new 148 
opportunity to develop small molecule drugs as therapeutic alternatives to anti-IL-23 149 
antibodies without systemic immune suppression. Biological agents may additionally 150 
cause unpredictable adverse events33 and can be costly on long-term use.34 It should 151 
also be mentioned that JAK inhibitors that are now being evaluated in their efficacy in 152 
autoimmune diseases are presumably not free from adverse effects, either, because of 153 
their effects of general immune suppression.35  154 
 Prostanoids including prostaglandin (PG) D2, PGE2, PGF2α, PGI2 and 155 
thromboxane A2 (TXA2) are oxygenated metabolites of arachidonic acid produced by 156 
sequential actions of cyclooxygenase (COX) and respective synthases, and act on their 157 
cognate receptors, DP for PGD2, EP1 to 4 for PGE2, IP for PGI2, FP for PGF2α , and TP 158 
for TXA2, to exert their actions.36 While prostanoids were previously regarded as 159 
immunosuppressants,37,38 recent studies have revealed their immunostimulatory actions 160 
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activation, and differentiation and expansion of Th subsets.39-41 Indeed, the PGE2-EP2 162 
and EP4 (EP2/EP4) signaling enhances Th1 differentiation by inducing the expression 163 
of an IL-12 receptor subunit, Il12rb2, and interferon-γ receptor, Ifngr1, thus facilitating 164 
IL-12 signaling and Th1 differentiation.42,43 Notably, this PGE2-EP2/EP4 signaling was 165 
also reported to synergize with IL-23 to facilitate Th17 cell expansion both in murine 166 
and human T cells.43-45 However, whether the PGE2-EP2/EP4 signaling is involved in 167 
induction of pathogenic Th17 cells, and, if so, how remains unknown. 168 
 In this study, we have examined how the PGE2-EP2/EP4 signaling and IL-23 169 
stimulation together regulate the generation of pathogenic Th17 cells. Through this 170 
analysis, we have identified the transcription mechanisms in addition to STAT3 that 171 
regulate Il23r expression and Th17 pathogenicity. We have further clarified the 172 
importance of the PGE2 signaling in the Th17-mediated immune inflammation in vivo, 173 
and found the correlation between PGE2-EP2/EP4 signaling and IL-23-IL-23 receptor 174 




























All animal experiments were approved by the Institutional Animal Care and Use 188 
Committee of Kyoto University Graduate School of Medicine, and complied with the 189 
National Institutes of Health Guide for the Care and Use of Laboratory Animals. 190 
C57BL/6NCrSlc mice were purchased from Shimizu laboratory, and Lck-Cre mice and 191 
B6.Cg-Nfkb1tm1Bal/J mice were purchased from Jackson Laboratory. Mice deficient in 192 
Ptger246 and mice with floxed Ptger247 were established in our laboratory. Mice with 193 
floxed Ptger4 was a kind gift of Richard Breyer.48  194 
 195 
Psoriasis models 196 
To induce psoriasis-like lesion in the ear in IL-23-induced psoriasis mouse model, mice 197 
were subcutaneously injected with IL-23 (500 ng; #130-096-677, Miltenyi, Bergisch 198 
Gladbach, Germany) once a day in one ear and with PBS in the contralateral ear as a 199 
control. In imiquimod (IMQ)-induced psoriasis mouse model, baselna cream containing 200 
10% IMQ was applied onto the ear of mice once a day. Ear thickness was then 201 
measured by a digital micrometer (#KM-BMB1-25, Mitutoyo, Kawasaki, Japan) every 202 
other day. In some experiments, an antagonist for EP4, AS1954813,49 suspended in 203 
0.5 % methylcellulose was orally administered twice a day or indomethacin and SC-236 204 
were administered by drinking water during the experimental period. 205 
 206 
Other methods 207 



















IL-23 mobilizes the endogenous COX-2-PGE2-EP2/EP4 signaling that enhances 212 
induction of Il23r expression in Th17 cells 213 
Given the previous findings43-45 that the PGE2-EP2/EP4 signaling enhances IL-23-214 
induced Th17 cell expansion, we questioned here whether and how this signaling 215 
contributes to pathogenic Th17 cell generation by IL-23. To investigate this issue, we 216 
first cultured CD4+ T cells from mouse spleen under the Th17-skewing condition (IL-6 217 
plus TGF-β1) for 4 days, and then incubated with IL-23 for additional 3 days. 218 
Consistent with our previous findings,43 the addition of PGE2 to the latter culture 219 
significantly enhanced IL-23-induced expansion and Il17a expression of Th17 cells 220 
(Fig. 1, A and B). Interestingly, we also noted that PGE2 markedly up-regulated IL-23-221 
induced expression of Il23r, which was mimicked by both EP2- and EP4-selective 222 
agonists (Fig. 1, C). Since both EP2 and EP4 activates PKA and Epac by increasing 223 
intracellular cAMP,36 we examined effects of compounds acting on these signaling, and 224 
found that a cAMP analogue, dibutyryl cAMP (db-cAMP), forskolin (FSK) and a 225 
phosphodiesterase inhibitor, IBMX, all synergized with IL-23 and significantly 226 
amplified IL-23-induced Il23r expression and IL-17A production in these cells (Fig. 1, 227 
D and E). Furthermore, the enhancement of Il23r expression was reproduced by a PKA 228 
agonist (N6-Bnz-cAMP, 300 µM) but not an Epac activator (8-pCTP-2’-O-Me-cAMP, 229 
300 µM) (Fig. 1, F), and, consistently, was ameliorated by treatment with a PKA 230 
inhibitor (H-89, 10 µM) (Fig. 1, G).  231 
 Notably, IL-23 stimulation significantly increased Ptgs2 (COX-2) gene 232 
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in the culture medium (Fig. 2, B). Moreover, incubation with non-selective COX 234 
inhibitor (indomethacin, 100 µM) or a selective COX-2 inhibitor (SC-236, 100 µM) but 235 
not a selective COX-1 inhibitor (SC-560, 100 µM) significantly blocked the induction 236 
of Il23r expression in response to both IL-23 alone and IL-23 and PGE2 in combination 237 
(Fig. 2, C and Fig E1, A). In addition, antagonists selective to EP2 (PF-04418948) or 238 
EP4 (ONO-AE3-208) also suppressed Il23r expression (Fig. 2, D). Intriguingly 239 
indomethacin and SC-236 suppressed the expression of Il23r induced by IL-23 and 240 
PGE2 to the level that these inhibitors achieved in the presence of IL-23 alone, 241 
suggesting that they cancelled the effect of exogenously added PGE2 (Fig. 2, D and Fig 242 
E1, A). Given that PGE2 added to the culture medium time-dependently degrades,50 243 
these results suggest that exogenously added PGE2 induces COX-2 and produces PGE2 244 
endogenously and continuously as we reported previously,51 which makes more 245 
contribution to Il23r induction, and that indomethacin and COX-2 inhibitor block this 246 
process. Indeed, the addition of stable EP2 and EP4 agonists overcame the Il23r 247 
suppression by indomethacin (Fig E1, B). Therefore, these data together suggest that IL-248 
23 stimulates Th17 cells to produce PGE2, which acts back to EP2 and EP4 on these 249 
cells to augment Il23r expression in a positive feedback manner. 250 
 251 
Induction of Il23r expression by IL-23 and PGE2-cAMP signaling is mediated 252 
through not only STAT3 but also CREB1 and NF-κB 253 
We then investigated transcription factors responsible for induction of Il23r expression 254 
in Th17 cells by IL-23 and PGE2-EP2/EP4 signaling. Because IL-23 activates STAT3 to 255 
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addition of STAT3 inhibitor VII suppressed Il23r expression not only by IL-23, but also 257 
by db-cAMP, and both (Fig. 3, A), indicating that the db-cAMP action was also 258 
mediated by STAT3. Consistently, Y705 phosphorylation of STAT3 was increased by 259 
db-cAMP at 5 and 30 min (Fig E2, A), which were ameliorated not only by the addition 260 
of STAT3 inhibitor VII but also by H-89 (Fig. 3, B), indicating the involvement of PKA 261 
in db-cAMP-mediated Y705 phosphorylation of STAT3. Intriguingly, the Y1007/1008 262 
phosphorylation of JAK2, a kinase responsible for STAT3 Y705 phosphorylation in 263 
Th17 cells, was enhanced by db-cAMP, and this enhancement was suppressed by Src 264 
Kinase Inhibitor I (Fig E2, B), indicating cAMP-PKA activates STAT3 through c-Src-265 
JAK2 pathway.  266 
 Although the above findings demonstrated that IL-23 and PGE2-cAMP 267 
signaling converge at STAT3 activation, it is well known that other STAT3 activators, 268 
such as IL-6 and IL-21, cannot substitute for IL-23 in the expansion of Th17 269 
population,32 indicating that STAT3 is not the sole transcription factor regulating 270 
expression of Il23r. Since PKA activates CREB1,36 we investigated the involvement of 271 
CREB1 in Il23r expression. Both KG-501, a CREB1 inhibitor,53 and RNAi for CREB1 272 
suppressed Il23r induction in response to db-cAMP, IL-23 or both, suggesting the 273 
involvement of CREB1 in Il23r expression in Th17 cells (Fig. 3, C and D). As IL-23 274 
signaling enhances endogenous PGE2 production via induction of COX-2 expression in 275 
Th17 cells (Fig. 2, A and B), the suppression of Il23r expression by inhibition or 276 
depletion of CREB1 could be due to inhibition of this endogenous PGE2 signaling for 277 
Il23r induction.  278 
 Furthermore, we detected an increase in S536 phosphorylation of NF-κB p65 279 
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S933 phosphorylation of NF-κB p105 subunit, a precursor of p50, in response to db-281 
cAMP alone and its combination with IL-23 in Th17 cells (Fig. 3, E). The latter is 282 
consistent with our previous finding in dendritic cells that PGE2-cAMP signaling 283 
activates the p50 subunit54 and a report that phosphorylation of p105 S933 is PKA-284 
dependent.55 We therefore examined the involvement of NF-κB in Il23r induction by 285 
using Nfkb1-deficient mice (p105 KO) or CTP-NBD, a NF-κB inhibitor. Interestingly, 286 
both genetic deficiency and pharmacological inhibition of NF-κB suppressed Il23r 287 
induction in response to db-cAMP, IL-23 and in combination (Fig. 3, F and G).  288 
  These results together suggest that the PGE2-EP2/EP4-cAMP-PKA signaling 289 
works together with IL-23 signaling to activate STAT3, CREB1 and NF-κB for 290 
induction of Il23r expression in Th17 cells.  291 
 292 
Gene signature induced by PGE2-EP2/EP4-cAMP signaling in CD4+ T cell 293 
populations primed with IL-6 and TGF-β1 294 
Since pathogenic Th17 cells should express various molecules in addition to IL-23R to 295 
exert their pathogenicity, we next examined how PGE2-EP2/EP4-cAMP signaling 296 
contributes to expression of such pathogenic genes in Th17 cells. CD4+ T cells were 297 
cultured under the Th17-skewing conditions with IL-6 and TGF-β1 for 3 days, then 298 
incubated with db-cAMP alone, IL-23 alone or both for 24 h, and subjected to 299 
microarray analysis. The numbers of genes up/down-regulated more than 2-folds by 300 
each stimulation were examined by Venn-diagrams (Fig. 4, A), and the genes expressed 301 
in each cluster (Table E, 1-8) were subjected to heat-map analysis (Fig E3, A) and gene 302 
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cluster is shown in the heat-map (Fig. 4, B). Cluster 1U included genes (e.g. Il17a, 304 
Il17f, Il1r1 and Il23r) that were up-regulated by db-cAMP, IL-23, or both in 305 
combination (Fig. 4 B, left). Cluster 2U included genes (e.g. Il22) that were increased 306 
by IL-23 alone or its combination with db-cAMP (Fig. 4 B, left). Cluster 3U 307 
encompasses various genes, which up-regulated by db-cAMP alone or its combination 308 
with IL-23 but not IL-23 alone. They include genes involved in cell migration and 309 
adhesion such as Ccr2, Cxcr4, Cx3cr1, Ccr6, S1pr1, Sema4f, Sema6c, Efna2, Sell, Selp 310 
and Itgb3, those involved in induction of IFN-γ, such as Il12rb2, Il18r1 and Il18rap, 311 
and those involved in cell activation such as Tlr4, Tgfb3, Rasa, Rasgrp2, Lat2, Txk and 312 
Rora (Fig. 4 B, left). Cluster 4U include genes such as Il1b, Il17rc, Il17re, Prkcq, 313 
Sema3c, Sema6a and Tlr12 that are up-regulated by the combination of IL-23 and db-314 
cAMP only (Fig. 4 B, left). On the other hand, the genes in Cluster 3D and Cluster 4D 315 
were down-regulated by db-cAMP, and contained Il10, Il2, Il4, Il5, Il13 and Il9, which 316 
are known as suppressive factors of inflammation, (Fig. 4 B, right). Expression of the 317 
representative genes was then confirmed by qRT-PCR analysis. Expression of Il17a, 318 
Il17f and Il23r in Cluster 1U, Il18r1, Il18rap, S1pr1, Ccr2, Cxcr4, Tlr4, Cxcl3, Cx3cr1, 319 
Sema4f, Sell and Txk in Cluster 3U and Il17re, Sema3c and Sema6a in Cluster 4U was 320 
all up-regulated (Fig. 4, C), and expression of Il10 in Cluster 3D was down-regulated by 321 
the addition of db-cAMP compared to incubation with IL-23 alone (Fig. 4, D). Thus, 322 
signaling through cAMP regulates expression of various genes that are not regulated by 323 
IL-23 alone, and may confer pathogenic property to Th17 cells. 324 
 325 
T cell-intrinsic PGE2-EP2/EP4 signaling is critical in IL-23-mediated psoriatic skin 326 
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Accumulating evidences suggest that Th17 cells become pathogenic via the IL-23-IL23 328 
receptor axis and play crucial roles in development of various autoimmune diseases 329 
including psoriasis.8,56,57 However, how these Th17 cells acquired the pathogenicity in 330 
vivo and to what extent the microenvironment of diseases contributes to this process 331 
remain to be defined. In the IL-23-induced psoriasis mouse model, gene expression of 332 
enzymes involved in PGE2 biosynthesis including Ptgs2 encoding COX-2, Ptges 333 
encoding membrane-associated PGE synthase, mPGES1, and Ptges2 encoding 334 
membrane-associated PGE synthase-2, mPGES2, were all up-regulated by IL-23 335 
administration into the skin (Fig E4, A), which is consistent with clinical observation 336 
that local PGE2 levels are elevated in blister fluids from human psoriatic skin.58 We 337 
therefore hypothesized that IL-23 possibly activates PGE2–EP2/EP4 signaling, which 338 
may contribute to psoriasis pathogenesis. 339 
 To test this hypothesis, we injected IL-23 into the skin of WT C57BL/6N mice 340 
as well as EP2 knockout (KO) mice46 with or without administration with a EP4 341 
antagonist, AS1954813,49 and assessed skin inflammation by ear thickness and 342 
histology. The EP2 deficiency or the EP4 antagonism alone reduced IL-23-induced ear 343 
swelling by half and attenuated edema and cell infiltration, and, when combined, led to 344 
nearly complete suppression of IL-23-dependent skin inflammation (Fig. 5, A and B). 345 
Blockade of EP2 and/or EP4 caused no alteration in PBS-injected control ear (Fig E3, 346 
B). To examine at which step of inflammation EP2 deficiency and EP4 antagonism 347 
exert their effects and whether it is related to generation of pathogenic Th17 cells, we 348 
digested ear tissues and analyzed CD4+ T cell populations in the skin by flow cytometry. 349 
While there were little numbers of cells producing IL-17A or IFN-γ in PBS-injected 350 
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populations were observed in the IL-23-injected ear as observed in psoriasis dermis in 352 
psoriasis patients.59 The IL-17A+IFN- γ+ CD4+ T cell population is suggested one 353 
population of pathogenic Th17 cells.60 This CD4+ T cell population was shown to arise 354 
in an IL-23-dependent manner from adoptively transferred T cells in transfer colitis,26 355 
and may reflect the Th17 to Th1 reprograming at inflammatory sites as shown for 356 
antigen-specific Th17 cells transferred to NOD mice.22 This accumulation was 357 
significantly reduced by blockade of either EP2 or EP4 alone and nearly completely 358 
suppressed by blockade of both EP2 and EP4 (Fig. 5, C and Fig E4, C-E). Consistently, 359 
expression of Il17a and Ifng that was up-regulated in the IL-23-injected ear was also 360 
reduced to the negligible levels by combined EP2 and EP4 blockade (Fig. 5 D, left and 361 
middle). Notably, EP2 and EP4 blockade also markedly inhibited enhanced expression 362 
of Il23r by IL-23 injection (Fig. 5 D, right). These findings together indicate that the 363 
EP2/EP4 signaling is indeed involved in the generation of pathogenic Th17 cells and 364 
elicitation of inflammation in this model. We then asked whether T-cell intrinsic 365 
EP2/EP4 signaling is responsible for these IL-23-induced phenotypes. To this end, we 366 
used EP2flox/flox mice47 and EP4flox/flox mice48 and generated EP2flox/flox EP4flox/flox Lck-367 
Cre+ mice. EP2flox/flox EP4flox/flox Lck-Cre+ mice showed no significant differences in the 368 
numbers of total cells, B cells, T cells, CD4 T cells, CD8 T cells, Th1 cells, Th17 cells 369 
and Treg cells in the thymus, spleen, lymph node and peripheral blood compared to 370 
control WT Lck-Cre+ mice (Fig E5, A). However, deficiency of both EP2 and EP4 371 
selectively in T cells prevented accumulation of Th17 cells in the ear and almost 372 
completely attenuated IL-23-induced skin inflammation (Fig. 5, E and F). These results 373 
together therefore suggest that the T cell-intrinsic PGE2-EP2/EP4 signaling is critical 374 
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imiquimod (IMQ)-induced psoriasis model8, in which we applied IMQ to the ear of WT 376 
or EP2 KO mice with or without EP4 antagonist for 6 days (Fig E6, A). We found that 377 
ear swelling was also significantly reduced by EP2 deficiency and EP4 antagonism and 378 
additively in combination similar to the results in IL-23-induced psoriasis model.  379 
 Given the above findings, we next examined the effects of COX inhibitors on 380 
skin inflammation in IL-23-induced psoriasis model (Fig E6, B and C). Treatment with 381 
indomethacin and SC-236 significantly suppressed the IL-23-induced ear swelling with 382 
concomitant suppression of IL-17A+ and IL-17A+ IFN- γ+ cells in the skin (Fig E6, B 383 
and C). These findings together suggest that COX inhibitors are as potent as EP2 and 384 
EP4 antagonists in suppressing skin inflammation at least in this model. 385 
 386 
PGE2 signaling positively correlates with the IL-23/Th17 pathway in human 387 
psoriatic skin biopsies 388 
Finally, to extrapolate our findings in mice to humans, we analyzed a public microarray 389 
dataset on gene expression profiles in skin biopsies from psoriasis patients and healthy 390 
control individuals,61 with a particular interest in correlation of PGE2 signaling and the 391 
IL-23/Th17 pathway. As expected, psoriatic lesional skin overexpressed Th17 signature 392 
genes (including IL23A, IL12B, IL23R, IL17A, IL17F, and IL22), STAT3 and NFKB1 393 
(encoding NF-κB p105) (Fig. 6, A). Moreover, psoriatic lesional skin overexpressed 394 
enzymes in PGE2 biosynthesis, e.g., PTGS2, PTGES and PTGES2, and the EP4 receptor 395 
(PTGER4) but under-expressed the PGE2 degrading enzyme, 15-PGDH (encoded by 396 
HPGD) (Fig. 6, A). Interestingly, expression of Th17 signature genes positively 397 
correlated with those involved in PGE2 biosynthesis (e.g. PTGES and PTGES2) and 398 
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the clinically effective anti-IL-23 therapy62 down-regulated gene expression of not only 400 
the IL-23/IL-17 pathway (e.g., IL23A, IL23R, IL17A) but also those in PGE synthesis 401 
like PTGES (Fig. 6, C and D). These findings support a potential crosstalk between the 402 
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DISCUSSION 404 
The IL-23-IL-23 receptor signaling plays a critical role in generation of pathogenic 405 
Th17 cells in autoimmunity.5-9 However, there remain several issues to be solved on this 406 
action, namely how this signaling gets promoted, what transcriptional mechanisms other 407 
than STAT3 are involved, what, along with the IL-23 signaling, makes Th17 cells 408 
pathogenic, whether and how much such mechanism operates in vivo and how relevant 409 
are the findings obtained in mouse to humans. Given the previously reported action of 410 
PGE2 on Th17 expansion,43-45 we focused here on PGE2 action in Th17 pathogenicity to 411 
address these issues. 412 
 We have first found that PGE2 synergizes with IL-23 and enhances Il23r 413 
expression through EP2 and EP4, a finding consistent with the findings in human Th17 414 
cells.44 We have then found that IL-23 stimulation induces PGE2 production in Th17 415 
cells and the IL-23-induced Il23r expression was attenuated by the treatment of cells 416 
with indomethacin or EP2/EP4 antagonists. These results thus suggest a previously 417 
unsuspected intrinsic amplification mechanism mediated by the PGE2-EP2/EP4 418 
signaling in Th17 cells that helps trigger the initial IL-23 responses in premature Th17 419 
cells. 420 
 We have further analyzed the transcriptional mechanisms underlying the 421 
synergistic action of IL-23 and PGE2, and found that this action is mediated by not only 422 
STAT3 but also CREB1 and NF-κB. The involvement of CREB1 is analogous to that in 423 
the PGE2-EP2/EP4-mediated Il12rb2 induction during Th1 cell differentiation,42 and 424 
may be consistent with the findings by Hernandez et al.63 showing that the 425 
CREB1/CRTC2 pathway regulates expression of IL-17A and IL-17F and that Th17 426 
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with the same molecule, IL-12Rβ1, to form IL-23 receptor and IL-12 receptor, 428 
respectively. It is interesting that the same pathway regulates expression of these two 429 
genes. We have also used T cells from p105 NF-κB1-deficeint mice and CTP-NBD and 430 
unraveled the involvement of NF-κB in the IL-23/cAMP-induced Il23r expression in 431 
Th17 cells. Consistent with these findings, we previously found that PGE2 through EP2 432 
or EP4 activates NF-κB1-containing NF-κB in various types of cells including 433 
macrophages and dendritic cells, and induces expression of inflammation-related genes 434 
including COX-2, which then produces PGE2 and amplifies this process.47,54,64 Our 435 
present findings thus further extend the importance of this COX-2-PGE2-EP2/EP4-NF-436 
κB loop to generation of Th17 cell pathogenicity. On the other hand, Boniface et al. 437 
suggested that PGE2-induced enhancement of Il23R expression in human Th17 cells 438 
was mediated by IL-1β-IL-1 receptor pathway.44 This is also a possibility in mice, 439 
because up-regulated expression of Il1r1 and Il1b was detected in Cluster 1U and 440 
Cluster 4U by our microarray analysis (Fig. 4 B, left). However, we assume that this 441 
mechanism does not critically operate in our experiment, because the addition of anti-442 
IL-1β antibody to the medium did not reduce the Il23r induction (Fig E7).  443 
 In addition to Il23r, our microarray analysis has revealed that stimulation of the 444 
EP2/EP4 signaling together with IL-23 facilitates expression of a variety of pathogenic 445 
Th17 signature genes (i.e. Il17a, Il17f, Il18r1 and Tgfb3). Interestingly, PGE2-EP2/EP4 446 
signaling also up-regulated the expression of various genes related to chemotaxis and 447 
migration such as S1pr1, Ccr2, Cxcl3, Cx3cr1, Cxcr4, Sema4f, Sell, Sema3c and 448 
Sema6a (Fig. 4 B, left). These results suggest that PGE2-EP2/EP4 signaling may 449 
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lesion. On the other hand, the addition of db-cAMP down-regulated expression of Il10, 451 
Il2, Il4 and Il9, which are known as suppressive factors for Th17 cells. Although some 452 
of these results such as IL-17A are consistent with the previous findings in human Th17 453 
cells,44 our study did not detect induction of IFN-γ and T-bet in cultured Th17 cells, 454 
which may reflect the stages of Th17 cells examined in each study.20,24,65 It should also 455 
be noted that our analysis was carried out in the whole CD4+ T cell population 456 
pretreated with IL-6 and TGF-β1 and stimulated with each stimulus, in which IL-17A+ 457 
cells comprise about 10%. Single cell RNA sequencing analysis is therefore desired to 458 
establish the gene expression signatures specific to Th17 cells matured with each 459 
stimulus.    460 
 Nonetheless, the most important point in our study was that the EP2/EP4 461 
signaling in Th17 cells identified here is critical in eliciting their pathogenicity in vivo 462 
in immune inflammation. We tested this issue in IL-23-induced mouse psoriasis model. 463 
Intriguingly, not only the systemic inhibition of EP2/EP4 signaling using the EP4 464 
antagonist in EP2 KO mice but also selective loss of EP2 and EP4 in T cells almost 465 
completely suppressed inflammation induced by IL-23. This was accompanied by 466 
suppression of accumulation of IL-17A+ and IL-17A+IFN- γ+ T cells and suppression of 467 
expression of Il17a, Ifng, Il23r genes in the lesion. These results suggest that the PGE2-468 
EP2/EP4 signaling functions critically in generation of pathogenic Th17 cells induced 469 
by IL-23 in situ. Of those Th17 cells, antigen-specific Th17 cells were shown to be 470 
specifically involved in the pathogenesis of mouse models of autoimmune inflammation 471 
including EAE,66 type 1 diabetes,22 and psoriasis.67 Quite recently it was also reported 472 
that mPGES1 is involved in generation of antigen-specific Th17 cells by regulating 473 
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combined together with these findings suggest that PGE2 plays an important role in 475 
psoriasis through the regulation of antigen-specific pathogenic Th17 cells. 476 
 The present study also showed that EP2 deficiency and EP4 antagonism also 477 
significantly suppressed the psoriatic inflammation in IMQ model. Notably, however, 478 
the combined EP2 deficiency and EP4 antagonism did not completely suppress ear 479 
swelling in this model, possibly because there is the IL-17-independent component in 480 
skin inflammation in this model.8  481 
 In this study, we also tested the effect of COX inhibitors in IL-23-induced 482 
psoriasis model, and found that COX inhibitors are as potent as EP2 and EP4 antagonist 483 
in suppressing psoriasis-like skin inflammation in this model. The question is whether 484 
COX inhibitors are beneficial in Th17-driven human autoimmune diseases. COX 485 
inhibitors, particularly Celecoxib, are used for treatment of the early stage of 486 
rheumatoid arthritis patients, and in patients with mild psoriatic arthritis.69 In these 487 
cases, COX inhibitors produce good symptomatic relief. While this effect is ascribed to 488 
their analgesic and general anti-inflammatory actions, our study suggests that it may be 489 
derived at least in part from their suppressive action on Th17-mediated pathology, a 490 
possibility that should be tested in future. On the other hand, COX inhibitors have less 491 
appreciable therapeutic benefits in established psoriasis and advanced RA in human 492 
patients. There are several plausible reasons. PG-mediated process may be critical in 493 
triggering pathogenic Th17 cell generation, but not so in advanced stage of diseases that 494 
might be dominantly regulated by established Th17 cells. Another may be due to the 495 
fact that PGs cause immune inflammation not by acting alone but by working with 496 
cytokines and boosting and modifying their actions. COX inhibitors may therefore exert 497 
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lessen the dose of the latter. Finally, COX inhibitors may divert arachidonate 499 
metabolism to leukotriene. Recent studies suggest that leukotrienes facilitate maturation 500 
and migration of Th17 cells.70,71 Further studies need to be conducted to unravel these 501 
issues.  502 
 Another topic to be discussed on PGE2 in psoriasis is its facilitative action in 503 
ultraviolet (UV) irradiation therapy, which at a glance contradicts our present findings 504 
on the facilitative action of PGE2 on Th17 pathogenicity. UVB-irradiation is an 505 
effective therapeutic treatment of psoriasis by inducing immunosuppression.72 We 506 
previously showed that UVB induces PGE2 in the epidermis and PGE2-EP4 signaling 507 
mediates systemic immunosuppression via the up-regulation of RANKL in 508 
keratinocytes and inducing regulatory T cells.73 Thus, the PGE2-EP4 signaling in this 509 
case facilitates immunosuppression and not immune activation. One point is that UVB 510 
does not penetrate to the dermis and the events it causes are within the epidermis, while 511 
IL-23-induced inflammatory events occur in the dermis. Another point is difference in 512 
the context, UVB irradiation in the UV therapy and IL-23 in psoriatic inflammation. 513 
PGE2 alone does not induce either effects, but functions directionally dependent on the 514 
context.   515 
 Finally, we have examined the relevance of our findings to human diseases by 516 
analyzing biopsy samples from psoriasis patients. Psoriatic lesional skin over-expressed 517 
not only Th17 signature genes including IL23A, IL12B, IL23R, IL17A, IL17F, IL22, 518 
STAT3 and NFKB1, but also those involved in PGE2 biosynthesis and function such as 519 
PTGS2, PTGES, PTGES2 and PTGER4. Expression of Th17 signature genes shows 520 
positive correlation with PTGES, PTGES2 and PTGER4, and negative correlation with 521 
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IL-23/IL-17 pathway (e.g., IL23A, IL23R, IL17A) but also those in PGE2 synthesis, 523 
suggesting that these two are functionally linked. These findings together with the 524 
finding by Kofler et al. that EP2 is expressed in Th17 cells from multiple sclerosis 525 
patients and that forced expression of EP2 in healthy Th17 cells triggers expression of 526 
pathogenic genes74 indicate that T cell-intrinsic EP2/EP4 signaling is critical in IL-23-527 
driven Th17 cell pathogenesis also in humans, and support a view that the combined 528 
inhibition of EP2 and EP4 is of value in therapeutic intervention of various Th17-529 
mediated diseases. 530 
 531 
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FIGURE LEGENDS 859 
Figure 1. IL-23 mobilizes the endogenous PGE2-EP2/EP4-cAMP-PKA pathway to 860 
facilitate Th17 expansion through synergistic Il23r induction. (A and B) Expansion 861 
of Th17 population by PGE2 and IL-23. CD4+ T cells were differentiated with TGF-β1 862 
and IL-6 to Th17 cells for 4 days, then stimulated with 100 nM PGE2 in the absence or 863 
presence of IL-23 (10 ng/ml) for additional 3 days. The cells were examined by FACS 864 
for IL-17A and IFN-γ (A) and by qRT-PCR for Il17a expression (B). (C-E) Effects of 865 
PGE2, agonists selective to each EP subtype and related compounds on Il23r expression. 866 
Th17 cells were incubated with 100 nM PGE2, an agonist selective to each EP subtype, 867 
ONO-DI-004 (EP1), ONO-AE1-259 (EP2), ONO-AE-248 (EP3), or ONO-AE1-329 868 
(EP4), 100 µM dibutyryl cAMP (db-cAMP), 10 µM forskolin (FSK), 100 µM 3-869 
isobutyl-1-methylxanthine (IBMX) with or without IL-23. Il23r expression (C and D) 870 
or IL-17A concentrations in culture supernatant (E) was examined. Expression of Il23r 871 
in Th17 cells stimulated with 100 µM db-cAMP, 300 µM N6-Bnz-cAMP (a PKA 872 
agonist), 300 µM 8-pCTP-2’-O-Me-cAMP (an Epac activator) (F), or H-89 (a PKA 873 
inhibitor) (G) with or without IL-23. All bars indicate mean ± SEM (n=3, each in A-G). 874 
p<0.05, **, p<0.01, ***, p<0.001. 875 
 876 
Figure 2. IL-23 self-amplifies its own signaling through a T cell intrinsic positive 877 
feedback COX-2-PGE2-cAMP-IL-23R loop. (A) Expression of COX-2 (Ptgs2) 878 
mRNA (A) in Th17 cells, or Th17 cells further cultured in the presence or absence of 879 
IL-23 for 3 days determined by qRT-PCR. (B) Concentrations of PGE2 in the culture 880 
supernatants of Th17 cells in the presence or absence of IL-23 and indomethacin 881 
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with PGE2 and IL-23 in the presence or absence of indomethacin for 3 days. (D) Il23r 883 
expression in Th17 cells stimulated with PGE2 and IL-23 in the presence or absence of 884 
EP2 (PF-04418948) and/or EP4 (ONO-AE3-208) antagonists for 3 days. All bars 885 
indicate mean ± SEM (n=3, each in A-D). *, p<0.05, **, p<0.01, ***, p<0.001. 886 
 887 
Figure 3. STAT3, CREB1 and NF-κB mediate cAMP and IL-23 induced Il23r 888 
expression in Th17 cells. (A) Effect of STAT3 inhibitor VII on Il23r expression in 889 
Th17 cells stimulated with db-cAMP and/or IL-23 for 3 days. (B) Western blot analysis 890 
of phospho-Y705 STAT3 and α-Tubulin as a loading control in Th17 cells cultured as 891 
described in Supplementary Methods. Representative images from 2 independent 892 
experiments are shown. (C) Effect of KG-501 on Il23r expression in Th17 stimulated by 893 
db-cAMP and/or IL-23. (D) Effects of RNA interference for CREB1 on Il23r expression 894 
(left) and Creb1 expression to confirm CREB knockdown efficiency (right). RNA 895 
interference, subsequent culture and stimulation of Th17 cells were performed as 896 
described in Supplementary Methods.  (E) Western blot analysis of phospho-S536 NF-897 
κB p65 (pp65), phospho-S933 NF-κB p105 (pp105), p65, p105/p50 and α-Tubulin in 898 
Th17 cells stimulated as described in Supplementary Methods. Representative images 899 
from 2 independent experiments are shown. (F and G) Effects of p105 KO (F) or CTP-900 
NBD (G) on Il23r expression in Th17 cells stimulated with db-cAMP and/or IL-23 for 3 901 
days. All bars indicate mean ± SEM. (n=3, each in A, C, F, and G, n=18 in B) *, p<0.05, 902 
**, p<0.01, ***, p<0.001. 903 
 904 
Figure 4. Activation of the COX-2-PGE2-EP2/EP4-cAMP pathway confers 905 
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Th17 cells stimulated with db-cAMP and/or IL-23. Venn-diagram analysis of two folds 907 
up- or down-regulated genes compared to the vehicle control upon each stimulus (One-908 
way ANOVA p<0.05, n=3) (left and right, respectively). (B) Heat-map analysis of 909 
expression of selected genes from each cluster. (C) qRT-PCR analysis of expression of 910 
representative genes of Th17 signature and immune activation in response to db-cAMP, 911 
IL-23 or db-cAMP and IL-23 in combination. (D) qRT-PCR analysis of expression of a 912 
representative inflammation suppressor gene, Il10, in response to db-cAMP, IL-23 or 913 
db-cAMP and IL-23 in combination. All bars in C and D indicate mean ± SEM. (n=3) *, 914 
p<0.05, **, p<0.01, ***, p<0.001. 915 
       916 
Figure 5. PGE2-EP2/EP4 signaling in T cells is required for IL-23-driven psoriatic 917 
skin inflammation. (A-D) Ear swelling (A) (n=16-17), representative Hematoxylin-918 
Eosin (HE) staining of the histological section of the ear (B) (n=3-4), number of IL-919 
17A+ and IL-17A+ IFN-γ+ CD4+ T cells of the ear (C) and gene expression of Il17a, Ifng 920 
and Il23r in the whole ear tissue (D) of WT or EP2 KO mice subcutaneously injected 921 
with IL-23 or PBS into the ear daily. An EP4 antagonist (AS1954813, 100 mg/kg) or 922 
vehicle was orally administered twice a day to the indicated mice. Bars in (B), 50 µm. 923 
Representative quantification results of the cell number in each population from 4 924 
independent FACS experiments are shown in (C) (n=3). Gene expression was indicated 925 
as fold-change compared to PBS-injected ear in (D) (n=3). (E and F) 926 
EP2flox/floxEP4flox/floxLck-Cre+ mice and control WT Lck-Cre+ mice were subjected to IL-927 
23-induced psoriasis model and the ear swelling (E) (n=11 and 7, respectively) and the 928 
number of IL-17A+ and IL-17A+ IFN-γ+ CD4+ T cells in the ear (F) (n=7 and 3, 929 


















Figure 6. PGE2 signaling positively correlates with the IL-23/Th17 pathway in 933 
human psoriatic skin biopsies. (A) Expression profiles of genes related to PGE2 934 
signaling and Th17 signature genes in human non-lesional (NL) or lesional (PL) skin 935 
biopsies from patients with psoriasis (n=58) and skin samples from healthy controls 936 
(HC, n=64). The z-score transformed values of microarray gene expression dataset 937 
GSE13355 were used. Th17 score was generated based on the average expression level 938 
of IL23A, IL12B, IL23R, IL17A, IL17F and IL22 genes. (B) Correlations of PTGES, 939 
PTGES2, HPGD and PTGER4 gene expression versus that of the Th17 score. Black, 940 
green and red dots indicate healthy control, non-lesional and lesional psoriatic biopsies, 941 
respectively. (C) Expression profiles of genes related to PGE2 synthases and Th17 942 
signature genes in human lesional skin biopsies from patients with moderate-to-severe 943 
psoriasis before (Baseline, n=22) or 12 weeks after treatment with an IL-23-specific 944 
mAb, Guselkumab, (Guselkumab, n=8). The z-score transformed values of microarray 945 
gene expression dataset GSE51440 were used. (D) Correlations of gene expression of 946 
PTGS2 and PTGES versus that of IL23R. P values were calculated by nonparametric 947 
Wilcoxon-Mann-Whitney tests (A, C) or nonparametric Spearman correlation test (B, 948 





















































































SUPPLEMENTARY METHODS 1 
Purification of CD4+ T cells and differentiation into Th17 cells 2 
Spleen was dissected from 6-10 week-old female C57BL/6N mice and cells were 3 
dissociated and collected. CD4+ T cells were purified from spleen cells by magnetic 4 
activated-cell sorting (MACS) using anti-CD4 microbeads (L3T4) (#130-049-201, 5 
Miltenyi) on auto-MACS (Miltenyi). The purity of CD4+ T cells was ~98 % (n=3) as 6 
assessed by FACS (FACS LSR Fortessa, BD Bioscience, San Jose, CA). Purified CD4+ 7 
T cells were differentiated into Th17 cells by the combination of TGF-β1 (1 ng/ml, 8 
#240-B-002, R&D systems, Minneapolis, MN) and IL-6 (20 ng/ml, R&D systems) in 9 
the presence of 5 µg/ml of anti-CD3 antibody (#14-0031-86, eBioscience, San Diego, 10 
CA) and 2.5 µg/ml of anti-CD28 antibody (#14-0281-86, eBioscience, San Diego, CA) 11 
in RPMI-1640 medium containing 10 % fetal bovine serum (FBS) for 4 days. 12 
Differentiated cells were then collected, washed and again plated for experiments with 13 
TCR stimulation. Experimental condition of each experiment is shown in the Results or 14 















Agonists selective to each PGE2 receptor subtype, EP1, EP2, EP3 and EP4 18 
(ONO-DI-004, ONO-AE1-259, ONO-AE-248 and ONO-AE1-329 respectively) and an 19 
EP4 antagonist, ONO-AE3-208,E1 were kindly provided by Ono Pharmaceutical Co., 20 
Osaka, Japan. An EP2 antagonist, PF-04418948, was synthesized according to the 21 
previous report.E2 An EP4 antagonist, AS1954813, was kindly provided by Astellas 22 
Pharmaceutical Co. (Tsukuba, Japan). PGE2, SC-560 and SC-236 were purchased from 23 
Cayman Chemical, Ann Arbor, MI. Dibutyryl cAMP (db-cAMP), forskolin, the 24 
N6-Bnz-cAMP, the 8-pCTP-2’-O-Me-cAMP, indomethacin and KG-501 were 25 
purchased from Sigma, St. Louis, MO. STAT3 inhibitor VII, Src Kinase Inhibitor-I, 26 
H-89, and CPT-NBD peptides were purchased from Calbiochem, San Diego, CA. 27 
Mouse IL-1β/IL-1F2 Antibody (AF-401-SP) was purchased from R&D systems. 28 
 29 













RNA purification and reverse transcription were performed by the RNeasy Mini Kit 31 
(Qiagen GmbH, Hilden, Germany) and the High-capacity cDNA Reverse Transcription 32 
Kit (ABI biosystems, Grand Island, NY) according to manufacturers’ instructions. 33 
cDNA, primers and FastStart DNA MasterPLUS SYBR Green (Takara, Shiga, Japan) 34 
were then mixed in 96-well PCR plate, and quantitative PCR was performed using 35 
CFX96 Real-Time System (Biorad). The following primers were used in this study;  36 
Gapdh: forward 5′-TGAACGGGAAGCTCAC-3′and reverse 5′37 
-TCCACCACCCTGTTGC-3′  38 
Il17a: forward 5′-TGTGAAGGTCAACCTCAAAGTC-3′ and reverse 5′39 
-GAGGGATATCTATCAGGGTCTTCA-3′  40 
Il23r: forward 5′-CCAAGTATATTGTGCATGTGAAGA-3′ and reverse 5′41 
-AGCTTGAGGCAAGATATTGTTGT-3′  42 
Ptgs2: forward 5′- TCGCAGGAAGGGGATGTTGT -3’ and reverse 5’- 43 













Creb1: forward 5′-CCAAACTAGCAGTGGGCAGT-3′ and reverse 5′45 
-CCCCATCCGTACCATTGTT-3′  46 
Il17f: forward 5′-GGAAGACAGCACCATGAAC-3′ and reverse 47 
5′-TGGACAATGGGCTTGACAG-3′   48 
Il18r1: forward 5′-GTTGAGATGGAGGATGAGGG-3′ and reverse 5′49 
-GACAGAAAACACGCAGGAG-3′  50 
Il18rap:  forward 5′-AGCCTTTAACTCTCCCCTG-3′ and reverse 5′51 
-ACACCACCTCTTCCTTCTTC-3′   52 
S1pr1: forward 5′-CATTCTCATCTGCTGCTTCATC-3′ and reverse 5′53 
-CCACAAACATACTCCCTTCCC-3′   54 
Ccr2: forward 5′-TGAGAAGAAGAGGCACAGG-3′ and reverse 5′55 
-CAACAAAGGCATAAATGACAGG-3′   56 
Cxcr4: forward 5′-ATCTGTGACCGCCTTTACCC-3′ and reverse 5′57 













Tlr4: forward 5′-CTTTCACCTCTGCCTTCAC-3′ and reverse 5′59 
-TACAATTCCACCTGCTGCC-3′ 60 
Cxcl3: forward 5′-GAACACCCTCAGGCTCAAGG-3′ and reverse 5′61 
-CCACCAACCAAAGAATACACATGG-3′  62 
Cx3cr1: forward 5′-ACAAAGAGAAAGGACAACGAG-3′ and reverse 5′63 
-TGATGCGGAAGTAGCAAAAG-3′  64 
Sema4f: forward 5′-AAGAAAGGCAAGAAAGAGGAC-3′ and reverse 5′65 
-CACATCAATAACCCCGCAC-3′ 66 
Sell: forward 5′-TGCCAAGAGACAAACAGAAG-3′ and reverse 5′67 
-CCAGCCAAATGAGAAATGCC-3′  68 
Txk: forward 5′-CACCGAAAGACATCTCTTCC-3′ and reverse 5′69 
-ACAACCCCAAACTGACCAC-3′ 70 
Il17re: forward 5′-ACAACCCCAAACTGACCAC-3′ and reverse 5′71 













Sema3c: forward 5′-ACAAAGACAGGAGGAAGGAG-3′ and reverse 5′- 73 
AGTGGCAATGCAGTGGTAG-3′ 74 
Sema6a: forward 5′-GCTCACTCTATGTTGCATTCTC-3′ and reverse 5′- 75 
ACTTTCCCTTACCCACCCAC-3′  76 
Il10: forward 5′-TGGGTGAGAAGCTGAAGACC-3′ and reverse 77 
5′-TTCATGGCCTTGTAGACACC-3′   78 
Ifng: forward 5′-ATCTGGAGGAACTGGCAAAA-3’ and reverse 79 
5’-TTCAAGACTTCAAAGAGTCTGAGGTA -3′  80 
Expression level of each gene was normalized to that of Gapdh and calculated relative 81 
to the expression in vehicle-treated group. 82 
 83 
Measurement of IL-17 and PGE2 concentration in culture supernatant of Th17 84 
cells 85 
IL-17 concentration in culture supernatant of differentiated Th17 cells stimulated with 86 













IL-17 Quantikine ELISA Kit (M1700, R&D systems) according to the manufacturer’s 88 
instruction. 89 
Th17 cells were stimulated with 10 ng/ml IL-23 for 3 days in the absence or presence of 90 
100 µM indomethacin and PGE2 concentration in culture supernatant was determined 91 
by a Prostaglandin E2 ELISA kit - monoclonal (514010, Cayman Chemical, Ann Arbor, 92 
MI) according to the manufacturer’s instruction. 93 
 94 
Gene expression of Th17 cells stimulated IL-23 and/or cAMP from microarray 95 
analysis 96 
CD4+ T cells were incubated in Th17-skewing condition for 4 days. Differentiated Th17 97 
cells were then stimulated by IL-23, db-cAMP or combination for 24 h. RNA was 98 
purified with an RNeasy Mini Kit, amplified and revers transcribed by the 99 
High-capacity cDNA Reverse Transcription Kit. cDNA was fragmented and labeled by 100 
a Low Input Quick Amp Labeling Kit (Agilent, Santa Clara, CA), and then hybridized 101 













scanned by Gene chip scanner 3000 system. Data were analyzed by GeneSpring 103 
software (Agilent Technology, Santa Clara, CA). 104 
 105 
Flow cytometry 106 
The medium was removed after each incubation, and cells were re-stimulated with 50 107 
ng/ml phorbol 12-myristate 13-acetate (PMA) (Sigma) and 500 ng/ml ionomycin 108 
(Sigma) in the presence of GolgiPlug (BD bioscience) for 4 h, followed by fixation and 109 
permeabilization with a fixation/permeabilization solution (Cytofix/Cytoperm, BD 110 
Pharmingen). Cells were then stained with anti-mouse CD45.2 antibody (eBioscience), 111 
anti-mouse CD4 antibody(BioLegend), anti-mouse IFN-γ antibody (eBioscience) and 112 
anti-mouse IL-17A antibody (BioLegend) followed by FACS analysis on LSR Fortessa 113 
(BD Bioscience). 114 
 115 













Differentiated Th17 cells were cultured with 10 ng/ml IL-23 for 3 days to induce 117 
IL-23R, rested to return STAT3 phosphorylation to the basal level, and then 118 
re-stimulated with 100 µM db-cAMP and/or 100 ng/ml IL-23 for 30 min with indicated 119 
compounds for indicated time. Total cell lysates were prepared with RIPA buffer 120 
(Sigma) containing a phosphatase inhibitor cocktail (PhosSTOP, Roche, Basel, 121 
Switzerland) and a proteinase inhibitor cocktail (Complete Protease Inhibitor Cocktail, 122 
Roche). Lysates were then subjected to SDS-PAGE (sodium dodecyl 123 
sulfate-poly-acrylamide gel electrophoresis) and separated proteins were transferred to a 124 
PVDF membrane (Millipore, Darmstadt, Germany). After blocking with an ECL 125 
Blocking Agent (GE Healthcare, Piscataway, NJ), membranes were incubated with 126 
primary antibodies, followed by incubation with secondary antibodies conjugated with 127 
horseradish peroxidase (GE). Signals were detected using an ECL Prime Western 128 
Blotting Detection Reagent (GE) on LAS-4000 (GE). Primary antibodies used were; 129 
mouse monoclonal anti-α-Tubulin antibody (clone DM1A, #T6199, Sigma), mouse 130 
monoclonal anti-GAPDH antibody (clone 6C5, #AM4300, Ambion, Austin, TX), rabbit 131 













Danvers, MA), rabbit monoclonal anti-phosphorylated STAT3 antibody (Y705; #9145, 133 
Cell Signaling Technology), rabbit monoclonal anti-phosphorylated STAT3 antibody 134 
(S727; #9134, Cell Signaling Technology), rabbit monoclonal anti-JAK2 antibody 135 
(clone D2E12, #3230, Cell Signaling Technology), rabbit monoclonal 136 
anti-phosphorylated JAK2 antibody (Tyr1007/1008; #3771, Cell Signaling Technology), 137 
rabbit monoclonal anti-NF-κB p65 antibody (clone D14E12, #8242, Cell Signaling 138 
Technology), rabbit monoclonal anti-phosphorylated NF-κB p65 antibody (S536; clone 139 
93H1, #3033, Cell Signaling Technology), rabbit monoclonal anti-p105/p50 antibody 140 
(#3035, Cell Signaling Technology), and rabbit monoclonal anti-phosphorylated p105 141 
antibody (S933; #4086, Cell Signaling Technology). 142 
 143 
RNA interference 144 
siRNA for mouse Creb1 (5′-UUGAACAACAACUUGGUUGCUGGGC-3′(sense) 145 
or 5′ -GCCCAGCAACCAAGUUGUUGUUCAA-3′  (antisense) and scrambled 146 
control siRNA were obtained from Invitrogen (Stealth RNAi, Carlsbad, CA). Th17 cells 147 













pmol of each siRNA using an Amaxa P3 Primary Cell 4D-Nucleofector X Kit with the 149 
program DN100 on a 4D-Nucleofector (Lonza, Basel, Switzerland) in 100 µl. After 150 
transfection for 4 h, cells were washed and stimulated with or without 10 ng/ml IL-23 151 
for 2 days , and then incubated with or without 100 µM db-cAMP for 1 day. Total RNA 152 
was prepared and then subjected to qRT-PCR analysis. 153 
 154 
Histology  155 
The ear tissues from psoriasis models were removed and fixed by 4 % 156 
Paraformaldehyde (PFA) for 48h at 4°C. Each ear tissues were embedded in paraffin, 157 
sectioned at 5 µm thickness, and then stained with hematoxylin-Eosin. 158 
 159 
Analysis of gene expression of human skin biopsies and mouse IL-23-treated ear 160 
from microarray datasets 161 
Microarray gene expression data of human skin biopsies were retrieved from Gene 162 













skin samples have been described previously.52,53 In brief, two biopsies were taken from 164 
each patient - one from lesional skin of each patient (involved sample) and the other 165 
from non-lesional skin (uninvolved sample), taken at least 10 cm away from any active 166 
plaque. One biopsy was obtained from each healthy control.52 Microarray gene 167 
expression data of IL-23-treated ear from mice was retrieved from GSE13335.53 Gene 168 
expression levels were transformed to z-score values. P values were calculated by 169 
nonparametric Wilcoxon-Mann-Whitney test, and correlations between expression 170 
levels of two genes were calculated by nonparametric Spearman correlation test. 171 
 172 
Statistical Analysis 173 
Data are shown in mean ± SEM. Statistical comparisons among more than two groups 174 
were conducted using One-way ANOVA with Bonferoni test. Statistical comparisons 175 
between two groups were conducted using Mann-Whitney test. P values of 0.05 or less 176 
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A_55_P2106358 G  





A_30_P01029744 G  
A_30_P01031674 G  
A_30_P01024836 G  
A_55_P2132646 G  
A_51_P423976 Crem 
A_65_P01319 Pde4b 
A_55_P2001262 G  
A_51_P484998 Hgf 








































A_30_P01019014 G  
A_30_P01018802 G  
A_55_P2148809 Zan 
A_55_P2042615 G  
A_51_P505868 Lhfp 
A_55_P2013184 Atp2b3 
A_51_P186798 G  
A_55_P1969962 Catsper3 







A_30_P01018712 G  
A_51_P121915 BC089597 
A_30_P01028426 G  
A_55_P2126259 Slc35e2 
A_55_P2174323 Pgpep1l 
A_30_P01018806 G  
A_55_P1955183 Crxos 




















A_30_P01023753 G  
A_55_P2120064 Gm2984 
A_30_P01028595 G  
A_55_P2269254 5730419F03Rik 
A_30_P01027938 G  
A_55_P2128734 Pbxip1 
A_51_P106249 Cmtm2b 





A_55_P2020035 G  






A_30_P01031286 G  
A_51_P123676 Synpo 
A_30_P01032395 G  
A_30_P01020338 G  
A_52_P577388 Epdr1 
A_65_P10913 Tgfb2 





A_30_P01026001 G  
A_52_P460957 Crem 
A_55_P2234084 G  
A_30_P01030451 G  
A_55_P2017826 Myb 














A_30_P01023132 G  
A_30_P01020686 G  
A_51_P234253 Sdcbp2 
A_51_P229664 Cd27 
A_55_P1966568 G  
A_30_P01020841 G  
A_52_P22763 Map2 
A_30_P01022829 G  





A_30_P01032069 G  
A_55_P2162543 G  







A_30_P01023097 G  
A_30_P01022080 G  
A_55_P2087963 G  




A_30_P01022578 G  
A_30_P01018048 G  
A_55_P2133632 Sipa1l2 
A_52_P163924 Trpd52l3 



























A_30_P01024596 G  
A_55_P2090330 Kcnmb4 
A_30_P01019779 G  
A_55_P2004551 Klra1 
A_30_P01018759 G  
A_55_P2096127 G  
A_55_P2370250 Syn3 
A_30_P01031842 G  
A_55_P2118866 Cmah 
A_55_P1962004 G  
A_55_P2074144 Tmprss11e 





A_55_P1968024 G  
A_55_P2021398 G  
A_55_P1975045 Sgcg 
A_30_P01031226 G  
A_30_P01027578 G  
A_55_P2087265 Ifitm1 
A_55_P2030672 Gm1587 
A_30_P01020408 G  















A_30_P01030530 G  




















A_30_P01022421 G  
A_30_P01032372 G  
A_51_P254646 Jdp2 







A_55_P1964594 G  
A_55_P1961608 Ypel4 
A_55_P1985831 G  
A_30_P01029085 G  
A_55_P2029902 Gab3 

















A_30_P01028164 G  
A_66_P109986 Cd33 
A_30_P01029324 G  
A_55_P2150476 G  
A_55_P2077522 G  
A_51_P483280 Prnp 
A_55_P2277620 Gm16523 
A_30_P01022763 G  
A_55_P2268790 4930445G23Rik 
A_55_P2258567 D930043N17Rik 









A_30_P01022950 G  





A_30_P01027097 G  
A_55_P2066553 Oacyl 






















A_30_P01031426 G  








A_30_P01032338 G  
A_52_P173442 Wscd2 
A_55_P2438722 Ifnar1 
A_30_P01026506 G  




A_30_P01028109 G  
A_55_P2147487 Cyth3 
A_51_P103541 Cacna1s 
A_30_P01033260 G  
A_55_P1971009 Gzme 







A_55_P2059657 G  
A_30_P01023293 G  
A_55_P2199118 Bend4 
A_30_P01032207 G  
A_30_P01031205 G  
A_55_P1967002 G  

















A_30_P01033663 G  
A_52_P585907 Pla2g4f 
A_55_P2180854 Mrgprg 
A_30_P01027293 G  
A_30_P01029470 G  
A_55_P2107383 Vmn2r96 
A_55_P2401971 AU015680 







A_55_P1960479 G  
A_55_P1968028 Tdgf1 





A_51_P461067 G  
A_55_P2062250 Gm5524 
A_30_P01022466 G  
A_30_P01018533 G  
A_52_P156452 Cmah 






A_30_P01027566 G  




























A_30_P01018318 G  
A_55_P2130660 Slitrk4 
A_52_P532227 S1pr1 
A_30_P01030847 G  
A_30_P01028877 G  




A_30_P01029731 G  
A_55_P2040497 Gm11517 
A_55_P2123566 Sipa1l2 
























A_30_P01023895 G  
A_30_P01019088 G  
A_30_P01033069 G  
A_55_P1994289 Gm10791 
A_52_P553890 Itgb3 
A_30_P01028896 G  
A_55_P2054409 Pira2 




A_30_P01029619 G  
A_30_P01023506 G  
A_66_P111562 Ccnd1 
A_30_P01017761 G  
A_30_P01031709 G  
A_52_P23225 Gpc3 
A_30_P01027076 G  
A_30_P01023050 G  
A_55_P2117465 Gm6559 
A_55_P2243828 LOC552901 
A_30_P01021882 G  
A_52_P602669 Serpinb6d 
A_55_P2106583 G  
A_55_P1974932 Olfr668 
A_55_P1954331 Murc 
A_30_P01019065 G  
A_55_P2113384 G  
A_30_P01019463 G  
A_55_P2135986 Ms4a4c 



















A_55_P2145224 G  
A_55_P2272748 G  





A_30_P01025429 G  
A_30_P01032232 G  
A_55_P2283116 4930478P22Rik 
A_30_P01022191 G  
A_55_P2099620 Hmx2 
A_55_P2044922 Gpr82 
A_30_P01030786 G  
A_51_P142896 Cd59a 
A_55_P2287260 Snap23 
A_55_P2048224 G  
A_30_P01018395 G  
A_52_P58359 Tlx1 
A_55_P2020338 Scml4 
A_30_P01031489 G  
A_30_P01024761 G  
A_55_P2131143 Dcaf17 
A_66_P116314 G  




A_30_P01023920 G  
A_55_P2086954 G  
A_30_P01017444 G  




















A_30_P01030603 G  
A_51_P391445 Ifngr1 
A_55_P2061273 Tbx6 
A_55_P2026894 G  
A_55_P2155146 Klrc3 
A_30_P01030998 G  
A_55_P2162935 Ntn1 
A_30_P01032852 G  
A_55_P2017677 Cap2 
A_30_P01018939 G  
A_30_P01028549 G  
A_55_P2020726 Gm16505 
A_55_P2030903 Rsph4a 
A_55_P2076744 G  
A_30_P01018535 G  
A_55_P2022504 1700019B21Rik 




A_55_P2032489 G  
A_30_P01025834 G  
A_52_P614207 G  
A_30_P01027590 G  
A_30_P01017808 G  








A_30_P01031851 G  
A_55_P2112772 Gabra3 
A_55_P2150377 G  



















A_30_P01024455 G  
A_55_P2054261 C2cd4b 




A_30_P01022071 G  
A_30_P01032178 G  
A_30_P01024457 G  
A_55_P2031403 Smim24 
A_30_P01019202 G  
A_55_P2045928 Btnl10 
A_30_P01025230 G  
A_30_P01022726 G  
A_55_P2014516 G  
A_55_P2164253 2010015L04Rik 
A_30_P01029367 G  
A_51_P381618 Pla1a 
A_30_P01024417 G  
A_30_P01022468 G  
A_55_P2149288 Cmya5 
A_30_P01029943 G  
A_30_P01020320 G  
A_30_P01026503 G  
A_55_P1961567 Ypel3 
A_30_P01019556 G  
A_30_P01029037 G  
A_55_P2162815 Fbxo31 
A_55_P2035509 Pyhin1 
A_30_P01028513 G  
A_52_P514407 Klra15 













A_30_P01030095 G  
A_55_P2064741 Nmb 




A_55_P2017169 G  
A_30_P01022733 G  
A_55_P1979950 G  
A_52_P161495 Bcl6 
A_52_P570820 Slc22a22 
A_30_P01024947 G  
A_51_P298066 Clnk 
A_55_P2237440 Gm13999 
A_30_P01028422 G  
A_30_P01021760 G  
A_30_P01023427 G  




A_30_P01031833 G  






A_30_P01020636 G  
A_55_P2184434 Eomes 
A_30_P01024775 G  
A_30_P01024742 G  
A_55_P2070296 D330025C20Rik 
A_55_P2008016 Armc3 
A_55_P2149921 G  
A_30_P01028539 G  
A_55_P2208682 B230334C09Rik 





















A_66_P135800 G  
A_51_P110341 Scgb3a1 
A_52_P500979 Pcsk1 
A_55_P1967591 G  
A_55_P2023290 1110032A03Rik 
A_30_P01028087 G  
A_55_P2058127 Pde4dip 
A_55_P1984401 Shank2 





A_66_P140688 G  
A_66_P103231 G  
A_30_P01023911 G  
A_55_P2010396 Pde4d 
A_30_P01023370 G  
A_51_P317640 Tgfb2 
A_55_P2133943 G  
A_55_P2227154 A530041M06Rik 




A_30_P01026901 G  
A_30_P01028225 G  
A_55_P2206269 9130403I23Rik 
A_55_P1957867 Gm3161 



























A_30_P01030639 G  
A_51_P483013 Arel1 





A_30_P01023079 G  
A_66_P139530 Gm5107 
A_51_P212420 Lama4 
A_30_P01018590 G  
A_66_P136844 Dppa2 
A_30_P01033579 G  
A_55_P2041457 G  
A_55_P2024150 Slco6b1 
A_55_P2417434 E130215H24Rik 























A_30_P01032241 G  
A_55_P2402258 4930432J09Rik 
A_55_P2081488 Pglyrp1 
A_55_P2332731 G  
A_55_P2064928 Nebl 
A_51_P497317 Tcp11l2 
A_30_P01025765 G  
A_55_P2202524 9330162012Rik 
A_66_P122719 G  




A_30_P01022541 G  
A_30_P01017796 G  








A_30_P01018690 G  





A_55_P2036086 G  
A_51_P132170 Ccdc141 
A_51_P448127 Khdc3 
A_30_P01025555 G  















A_30_P01019196 G  
A_30_P01022138 G  
A_55_P2223851 G  
A_51_P469688 Syt17 
A_30_P01024849 G  
A_30_P01023056 G  
A_30_P01019238 G  
A_51_P259975 Aspa 
A_55_P1987291 4833424O15Rik 
A_30_P01018325 G  
A_55_P2138739 G  
A_30_P01018311 G  
A_55_P2161219 Thsd7a 
A_55_P2022519 Tmem108 
A_30_P01024167 G  
A_51_P196695 Il7r 
A_55_P2084739 Gcnt1 
A_30_P01029056 G  
A_55_P1971010 Gzme 
A_52_P423247 Pde4b 
A_30_P01032466 G  
A_55_P1960999 Pigr 

















































































A_30_P01031856 G  
A_55_P2004536 Klra4 









A_30_P01028500 G  









A_30_P01023824 G  
A_55_P2169923 Cacna1s 
A_55_P2062802 G  
A_55_P2223282 B130019D13Rik 
A_30_P01021320 G  
A_30_P01027981 G  
A_52_P517984 Usp50 
A_66_P128761 Pydc3 
A_30_P01025525 G  



















A_55_P1957871 G  
A_55_P2013356 Renbp 
A_55_P2058028 G  
A_55_P2051622 Gm8479 
A_55_P1971938 Atp2b2 
A_66_P105596 G  
A_51_P473498 Gpr171 
A_55_P2011491 G  
A_30_P01023578 G  
A_30_P01032461 G  
A_55_P2060376 Gzmg 
A_51_P464900 Gabbr1 












A_55_P2100197 G  
A_30_P01021190 G  
A_55_P2077501 G  
A_30_P01032661 G  
A_55_P2019838 LOC102635555 
A_55_P2025937 G  
























A_55_P2077515 G  
A_52_P730743 G  
A_55_P1989738 4930426L09Rik 







A_30_P01029179 G  
A_55_P1988658 4930558N11Rik 
A_30_P01030381 G  
A_30_P01031149 G  
A_51_P413740 Ftcd 
A_55_P2269289 Dgkg 
A_30_P01032026 G  
A_55_P2378486 Kcnma1 
A_30_P01027555 G  
A_55_P2050988 G  
A_51_P326229 Ddx25 
A_55_P2393734 4933421H12Rik 
A_55_P2008835 G  
A_55_P2111380 Ctnnd2 
A_30_P01021778 G  
A_30_P01026400 G  
A_55_P2048448 Klra23 
A_30_P01024983 G  
A_55_P2005470 Mfap4 
A_30_P01031285 G  



















A_30_P01032380 G  
A_30_P01023510 G  
A_30_P01031079 G  
A_30_P01020553 G  
A_55_P1969698 5430402E10Rik 
A_55_P2335768 4831407H17Rik 
A_30_P01024729 G  
A_51_P422540 Paqr8 
A_51_P440460 Hip1r 
A_30_P01017646 G  
A_30_P01022515 G  
A_30_P01021571 G  
A_30_P01022305 G  
A_55_P2109633 Tcf7 
A_55_P2083629 Tle2 
A_30_P01032048 G  








A_30_P01018708 G  
A_52_P123655 A630023P12Rik 
A_55_P2364516 AA060545 
A_30_P01029394 G  
A_55_P2178800 Ugt1a10 



















A_30_P01023919 G  
A_30_P01018847 G  
A_30_P01019879 G  
A_30_P01032204 G  
A_30_P01018751 G  
A_52_P667477 Fyco1 








A_30_P01019369 G  
A_51_P116906 Rapgef3 
A_51_P489138 Sptb 













A_30_P01031257 G  
A_55_P2185068 Gm3002 


















A_30_P01018930 G  
A_55_P2232057 AU022793 
A_51_P220343 Wisp1 
A_55_P1982227 G  
A_30_P01024650 G  
A_30_P01025307 G  
A_55_P2028847 G  
A_55_P2173039 G  
A_30_P01028959 G  
A_66_P102878 Olfr726 
A_55_P1965564 Gm15085 
A_55_P2156515 G  
A_55_P2161347 Acmsd 
A_55_P2039646 G  
A_30_P01023052 G  
A_55_P2132888 Sdcbp 
A_30_P01024653 G  
A_30_P01018360 G  
A_30_P01021347 G  
A_51_P183051 Upb1 


























A_30_P01031678 G  
A_51_P240693 Tecpr1 
A_30_P01025404 G  
A_30_P01031292 G  
























A_30_P01028640 G  
A_55_P2179074 Ciita 
A_55_P2143025 Sema3c 
A_30_P01033650 G  
A_55_P1983523 Cd300ld 
A_30_P01031906 G  
A_30_P01029988 G  
ERCC-00138_246 G  
A_30_P01021841 G  
A_55_P2126072 G  
A_55_P2350553 4933405D12Rik 
A_55_P2079064 Ppnr 
A_30_P01033285 G  
A_51_P474459 Socs3 
A_30_P01023629 G  
A_30_P01026288 G  
A_30_P01020935 G  
A_30_P01019221 G  
A_30_P01029761 G  
A_55_P2172058 Trim55 
A_30_P01030183 G  
A_30_P01025039 G  
A_51_P212782 Il1b 
A_30_P01027263 G  
A_30_P01025011 G  
A_30_P01023923 G  
A_30_P01020331 G  
A_30_P01023521 G  
A_30_P01023091 G  
A_30_P01021631 G  
A_55_P2171303 Bin3 
A_30_P01029928 G  
A_30_P01017753 G  
A_30_P01027585 G  
A_52_P430304 Fam186b 
A_30_P01026777 G  
A_55_P2325568 1700060J05Rik 













A_30_P01022182 G  
A_55_P2052913 G  
A_55_P1960411 Lrrc23 
A_30_P01019696 G  
A_30_P01020060 G  
A_30_P01020888 G  
A_55_P2091330 Olfr871 






A_30_P01030364 G  
A_30_P01027780 G  
A_51_P127738 Scn2a1 
A_55_P2383523 1700123I01Rik 




A_30_P01021518 G  
A_30_P01020765 G  
A_66_P114333 Tlr12 
A_30_P01028455 G  
A_30_P01032259 G  
A_30_P01021422 G  
A_55_P2085727 Stk38 
A_30_P01021468 G  
A_55_P2419483 4732460I02Rik 
A_55_P1958039 Klra16 





















A_30_P01026963 G  
A_55_P2026420 Pou6f1 
A_55_P2066878 Kcnj13 
A_55_P2128582 G  
A_55_P2092717 Trim43b 




A_30_P01025016 G  
A_30_P01031844 G  
A_55_P1997421 Gm5416 
A_30_P01022699 G  
A_30_P01025043 G  
A_30_P01028130 G  
A_55_P1957277 Obfc1 
A_30_P01020539 G  
A_55_P2403874 D230014I24Rik 
A_55_P1980868 Gm6313 
A_30_P01023317 G  
A_30_P01022249 G  
A_30_P01026161 G  
A_55_P1998827 Prim2 
A_55_P2019533 Zscan4c 
A_30_P01025818 G  
A_30_P01020406 G  
A_55_P2181029 G  
A_55_P2025038 Cpe 
A_30_P01031340 G  

























A_30_P01032387 G  
A_55_P2119633 Gnal 
A_66_P131931 Aurkc 
A_30_P01024656 G  
A_52_P497021 Spred3 
A_55_P2165224 4930467J12Rik 
A_30_P01026625 G  
A_55_P2171196 G  
A_30_P01027893 G  
A_51_P260265 Hoxd4 
A_52_P616332 Atp10d 
A_55_P2143081 G  






A_55_P2115260 G  
A_66_P136569 G  
A_30_P01028376 G  
A_52_P964651 Fam65c 
A_30_P01026211 G  
A_55_P2110171 G  
A_55_P2108086 G  
A_55_P2064386 Gm4098 
A_30_P01026654 G  
A_30_P01030450 G  
A_30_P01027602 G  
A_55_P1999756 G  
A_55_P2248320 C430003N24Rik 
A_55_P1962289 G  




A_30_P01019408 G  
















A_30_P01028299 G  




A_30_P01028919 G  
A_30_P01032993 G  
A_55_P1955427 Cux1 
A_55_P1958329 G  
A_30_P01018695 G  
A_30_P01018313 G  
A_55_P1988388 Gm2347 
A_55_P1957245 G  




A_30_P01028796 G  









































A_55_P2119927 G  
A_55_P2127977 G  
A_66_P137556 Tle1 
A_55_P2293351 Slc2a4rg-ps 
A_30_P01017519 G  
A_30_P01023472 G  
A_30_P01033074 G  
A_55_P2070105 G  
A_30_P01019307 G  
A_30_P01029310 G  
A_30_P01022226 G  
A_30_P01029091 G  
A_66_P116860 5031434O11Rik 
A_30_P01020677 G  
A_55_P1966155 Wfdc6b 
A_30_P01023532 G  
A_30_P01019630 G  
A_30_P01028922 G  





A_30_P01019783 G  
A_55_P2130695 Armc4 
A_30_P01024134 G  
A_30_P01018888 G  
A_30_P01028942 G  















A_30_P01020996 G  
A_55_P1977938 Fcgbp 
A_55_P2082519 Olfr883 
A_30_P01032602 G  
A_55_P1958951 G  
A_30_P01021398 G  
A_30_P01024624 G  
A_55_P2075065 Gm10471 
A_30_P01032240 G  
A_55_P2311208 C130045F17Rik 
A_30_P01018774 G  
A_52_P667287 Cers6 
A_55_P2180481 1810020O05Rik 
A_30_P01022128 G  
A_55_P2213968 4933416M07Rik 
A_30_P01019634 G  
A_52_P508317 Erlec1 
A_55_P1977473 Dab2 
A_30_P01030677 G  
A_55_P2051094 Rorc 
A_55_P2112270 Gm6556 
A_55_P2065506 G  
A_55_P2105403 Nrxn3 
A_55_P2040873 Gm867 
A_30_P01026907 G  
A_55_P2006625 G  
A_52_P468068 Tchh 
A_55_P1968103 Pla2g2c 








A_30_P01022204 G  














A_30_P01019135 G  
A_30_P01021718 G  
A_55_P2259889 LOC102632493 





A_30_P01030411 G  
A_30_P01017989 G  
A_55_P2014427 Il17re 
A_55_P1974622 G  
A_55_P2077218 Spef1 
A_30_P01028994 G  
A_30_P01030141 G  
A_30_P01025370 G  
A_55_P1964902 Gm3014 
A_55_P2249849 Sema6a 
A_55_P1966470 G  
A_51_P184484 Mmp13 




A_30_P01019902 G  
A_30_P01033039 G  
A_55_P2153496 Ppp2r3d 
A_55_P2005984 Wfdc15b 
A_30_P01031894 G  
A_55_P2218483 A730093L10Rik 
A_30_P01033525 G  
A_30_P01027071 G  
A_51_P150745 Olfr1044 
A_30_P01032097 G  
A_55_P2004179 Col2a1 
A_55_P2053236 G  
A_55_P2420983 6330575P09Rik 
A_30_P01026306 G  





















A_30_P01029853 G  
A_30_P01025615 G  
A_55_P2023607 Ikzf1 
A_51_P486188 Pabpc2 









A_30_P01025737 G  
A_30_P01019416 G  
A_30_P01022612 G  
A_52_P259508 Prkcq 
A_30_P01022038 G  
A_55_P2242089 Cog5 




A_30_P01030554 G  
A_55_P2019620 Vmn2r94 
A_30_P01022174 G  
A_55_P2408848 Lgr4 
A_30_P01020577 G  
A_30_P01017726 G  
A_55_P2102464 G  
A_55_P1962781 G  














A_30_P01024104 G  
A_30_P01021723 G  
A_30_P01027051 G  
A_55_P2082684 Krt12 
A_55_P1966608 G  
A_55_P2266679 Mettl21c 
A_55_P2065429 G  
A_55_P2364315 D030002E05Rik 
A_30_P01021199 G  
A_30_P01030589 G  
A_30_P01019520 G  
A_51_P424641 Sirt4 
A_30_P01032902 G  




A_30_P01029327 G  
A_30_P01032254 G  
A_51_P284426 Cstad 
A_55_P2043782 Trpm1 
A_30_P01024577 G  
A_55_P2325758 A430054B03 
A_30_P01031901 G  
A_30_P01020426 G  
A_30_P01023251 G  
A_55_P2333126 Mgea5 
A_55_P1977451 G  
A_55_P2065726 Snx29 
A_30_P01021610 G  
A_55_P1966770 G  
A_55_P2125588 Pdgfa 
A_55_P2025775 G  
A_55_P2381921 4930406D14Rik 
A_30_P01022472 G  
A_55_P2045158 Mlxipl 
A_30_P01032514 G  
A_55_P1959753 Top3b 














A_30_P01025798 G  
A_30_P01023172 G  
A_55_P1989812 G  
A_30_P01023118 G  
A_30_P01023385 G  
A_30_P01030643 G  
A_55_P2006008 Serpinb1a 
A_52_P398989 Cytip 
A_30_P01028292 G  
A_30_P01018167 G  
A_30_P01026636 G  
A_30_P01021342 G  
A_30_P01023902 G  
A_30_P01025624 G  
A_55_P2259500 D130012P04Rik 
A_30_P01031220 G  
A_55_P2246014 C130051F05Rik 
A_51_P121607 4930546C10Rik 
A_30_P01026456 G  
A_30_P01018358 G  
A_55_P2086455 Wscd2 
A_30_P01028737 G  
A_55_P2085015 Vsx1 
A_51_P382849 Emb 
A_55_P2139464 G  
A_55_P1998781 Zcchc16 
A_55_P1997544 G  
A_55_P2075569 Smim23 
A_30_P01026305 G  
A_55_P2122633 Airn 
A_55_P1966721 9930105H17Rik 




A_30_P01032903 G  
A_52_P38964 Sap25 

















A_30_P01019457 G  
A_55_P2098941 1700110I01Rik 
A_30_P01026925 G  




A_30_P01018776 G  
A_55_P2127854 G  
A_30_P01031732 G  
A_30_P01033290 G  
A_51_P411917 Gata6 







A_30_P01025362 G  
A_55_P2144090 G  
A_30_P01026215 G  
A_55_P2049261 G  



























A_55_P2007467 G  
A_55_P1958172 Ms4a5 
A_55_P2211164 5330406M23Rik 










A_55_P2119882 G  
A_30_P01028837 G  
A_55_P1958758 Olfr965 
A_55_P2058831 Fancc 
A_30_P01024460 G  
A_55_P2360501 G  
A_55_P1981366 Lamc2 
A_66_P136132 G  
A_55_P2200618 LOC552902 






A_30_P01026880 G  
A_51_P158814 Marveld1 
A_66_P109731 G  
A_55_P2007981 Fmn2 
A_55_P2096515 Gm10706 
A_30_P01018987 G  
A_55_P2208260 D230019N24Rik 
A_55_P1971287 Olfr1436 
A_30_P01021544 G  
A_55_P2275402 9330177L23Rik 
A_55_P2063736 Gp49a 
















A_30_P01023847 G  
A_30_P01021174 G  
A_55_P1954985 G  




A_30_P01027527 G  
A_30_P01021556 G  
A_55_P1970144 Slc16a14 
A_30_P01028537 G  
A_30_P01019085 G  
A_51_P245090 Aqp3 
A_55_P1988108 Mrc1 
A_30_P01024483 G  
A_30_P01033047 G  
















A_55_P2030354 G  
A_55_P2094040 G  
A_55_P2106043 Bsx 
A_30_P01030933 G  
A_51_P111962 Bean1 
A_30_P01032018 G  
A_55_P2130249 Sh3gl2 




















































































A_55_P2128229 G  
A_55_P2039027 Speer6-ps1 
A_51_P115005 Edn1 














A_55_P2009708 G  
A_55_P1984655 Smtnl2 
A_66_P132249 Akr1c13 



















































































































































































































A_30_P01030879 G  
A_51_P156438 Slc25a33 
A_55_P1978052 Pet112 
A_52_P248403 G  
A_55_P2033680 G  











































































































A_30_P01030169 G  

































GO ACCESSION GO Term p-value corrected p-value -logP gene 







GO:0032101 regulation of response to external 
stimulus 
1.03E-

































positive regulation of cytokine 
production involved in inflammatory 
response 
7.20E-
06 0.008231741 2.08E+00 
Il17f 
Il17a 
GO:1900015 regulation of cytokine production involved in inflammatory response 
1.54E-
05 0.014684372 1.83E+00 
Il17f 
Il17a 






















GO:0031328 positive regulation of cellular biosynthetic process 
6.72E-













positive regulation of nucleobase-
containing compound metabolic 
process 
4.74E-







GO:0045944|GO:0010552|GO:0045817 positive regulation of transcription from RNA polymerase II promoter 
6.37E-


















GO:0051173 positive regulation of nitrogen 
compound metabolic process 
6.47E-







GO:0009891 positive regulation of biosynthetic process 
7.62E-






























p-value -logP gene 
GO:0005615 extracellular space 
8.63E-






GO:0031012 extracellular matrix 
8.10E-





















GO ACCESSION GO Term p-
value 
corrected 




10 1.73E-05 4.76E+00 
Cacna1s Synpo Tgfb3 Ms4a4b Cd59a Hc Il7r Selp Cd27 
Ccr2 Lag3 Cd160 Sytl2 Gpnmb Gabbr1 Vmn1r24 Gpc3 
Sema4f Cd24a Klrc1 Pde4b Ms4a1 Ntrk3 S1pr1 Itgb3 
Slc22a22 Nt5e Cxcr4 Pla2g4f Ifnlr1 Camk2n1 Abca1 Plaur 
Atp6v0d2 Dcc Tdgf1 Shc4 Rasa3 Catsper3 Atp2b2 Sgcg 
Il12rb2 Abcb4 Grm1 Slc8a3 Shank2 Cacna1h Gria4 
Ms4a4b Scn3b Klra4 Klra1 Klrc1 Ntrk3 Cx3cr1 Slc17a3 
Sell Pde4d Fasl Lzts3 Slco6b1 Trpm6 Kcng1 Ntrk3 Sgip1 
Vmn1r203 Tmprss11e Kcnmb4 Adra1b P2rx4 Adora2a 
Sipa1l1 Gabra3 Klrd1 Klri2 Smo Slc52a3 Sdcbp Wwc1 
Cyth3 Klrc3 Dmd Akap7 Clstn3 Cacnb2 Catsperd Kcnma1 













GO:0071944 cell periphery 1.27E-08 2.92E-04 3.53E+00 
Cacna1s Gpr65 Arrdc4 Synpo Tgfb3 Cysltr2 Ms4a4b 
Cd59a Hc Amigo2 Slc46a2 Il7r Abcb9 Ptprz1 Selp Cd27 
Lat2 Ccr2 Lag3 Cd160 Sytl2 Tmod1 Cpm Olfr1414 Grb7 
Tspan2 Rab19 Olfr983 Paqr8 Gpnmb Khdc3 Cldn10 
Gabbr1 Olfr959 Il1r2 Vmn1r24 Gpr171 Prnp Sptb Slc16a9 
Bst1 Gabbr1 Ramp1 Vcl Tbc1d30 Fzd10 Gpc3 Sema4f 
Cd24a Magi1 Klrc1 Svil Pde4b Fam110c Ms4a1 Ntrk3 
Klra15 S1pr1 Itgb3 Sla2 Slc22a22 Nt5e Cxcr4 Pla2g4f 
Ifnlr1 Camk2n1 Abca1 Plaur Atp6v0d2 Txk Ramp3 Igflr1 
Lsp1 Klra16 P2ry14 Pigr Dcc Cxcr6 Tdgf1 Shc4 Rasa3 
Catsper3 Atp2b2 Olfr668 Sgcg Il12rb2  Abcb4 Grm1 
Slc8a3 Shank2 Cacna1h Gria4 Ms4a4b Vmn2r48 Rasa3 
Ptprz1 Scn3b Cd300lf Klra4 Klra1 Klrc1 Olfr1446 Ntrk3 
Dgkb Cx3cr1 Vmn2r91 Slc17a3 Sell Pde4d Atp2b3 Olfr54 
Wwox Fasl Cap2 Samhd1 Lzts3 Slc16a5 Slco6b1 Gpr146 
Tspan2 Cdcp1 Trpm6 Piezo2 Gpr82 Klra23  Efna2 
Cx3cr1 Kcng1 Arl4d Fgfr1 Sgip1 Pde6a Inadl Vipr1 
Vmn1r203 Ptpn13 Vmn2r60 Tmprss11e Olfr1320 Nid1 
Ifitm1 Kcnmb4 Olfr701 Adra1b Ramp3 P2rx4 Vmn2r96 
Pde4b Art4 Adora2a Sipa1l1 Gabra3 Klrd1 Klri2 Smo Prrt1 
Slc52a3 Slc16a2 Sdcbp Wwc1 Ermn Rasgrp2 Ifitm1 Cyth3 
Zan Cat Klrc3 Sema6c Gpr114 Thsd7a Ntn1 Cxcr6 Dmd 
Cacna1s Ptpn13 Akap7 Olfr566 Clstn3 Mrgprg Cfh 
Cacnb2  Dgkg Snap23 Caln1 Catsperd Kcnma1 Pde4b 

















08 0.0011393 2.94E+00 
Cacna1s Gpr65 Arrdc4 Synpo Tgfb3  Cysltr2 Ms4a4b 
Cd59a Hc Amigo2 Slc46a2 Il7r Abcb9 Ptprz1 Selp Cd27 
Lat2 Ccr2 Lag3 Cd160 Sytl2 Cpm Olfr1414 Grb7 Tspan2 
Rab19 Olfr983 Paqr8 Gpnmb Cldn10 Gabbr1 Olfr959 Il1r2 
Vmn1r24 Gpr171 Prnp Sptb Slc16a9 Bst1 Gabbr1 Ramp1 
Vcl Tbc1d30 Fzd10 Gpc3 Sema4f Cd24a Magi1 Klrc1 Svil 
Pde4b Ms4a1 Ntrk3 Klra15 S1pr1 Itgb3 Sla2 Slc22a22 
Nt5e Cxcr4 Pla2g4f Ifnlr1 Camk2n1 Abca1 Plaur Atp6v0d2 
Txk Ramp3 Igflr1 Lsp1 Klra16 P2ry14 Pigr Dcc Cxcr6 
Tdgf1 Shc4  Rasa3 Catsper3 Atp2b2 Olfr668 Sgcg 
Il12rb2 Abcb4 Grm1 Slc8a3 Shank2 Cacna1h Gria4 
Ms4a4b Vmn2r48 Rasa3 Ptprz1 Scn3b Cd300lf Klra4 
Klra1 Klrc1 Olfr1446 Ntrk3 Dgkb Cx3cr1 Vmn2r91 Slc17a3 
Sell Pde4d Atp2b3 Olfr54 Wwox Fasl Cap2 Samhd1 Lzts3 
Slc16a5 Slco6b1 Gpr146 Tspan2 Cdcp1 Trpm6 Piezo2 
Gpr82 Klra23 Efna2 Cx3cr1 Kcng1 Ntrk3 Arl4d Fgfr1 
Sgip1 Pde6a Inadl Vipr1 Vmn1r203 Ptpn13 Vmn2r60 
Tmprss11e Olfr1320 Ifitm1 Kcnmb4 Olfr701 Adra1b 
Ramp3 P2rx4 Vmn2r96 Pde4b Art4 Adora2a Sipa1l1 
Gabra3 Klrd1 Klri2 Smo Prrt1 Slc52a3 Slc16a2 Sdcbp 
Wwc1 Rasgrp2 Ifitm1 Cyth3 Zan Cat Klrc3 Sema6c 
Gpr114 Thsd7a Cxcr6 Dmd Cacna1s Ptpn13 Akap7 
Olfr566 Clstn3 Mrgprg Cfh Cacnb2 Dgkg Snap23 Caln1 
Catsperd Kcnma1 Pde4b Pde4d Olfr726 Igf1r Cd33 


















07 0.0024761 2.61E+00 
Cd59a Il7r Selp Cd27 Ccr2 Lag3 Cd24a Klrc1 Ms4a1 
S1pr1 Itgb3 Cxcr4 Abca1 Il12rb2 Klra4 Klra1 Klrc1 Sell 







06 0.0134296 1.87E+00 
Dusp10 Rapgef3 Tgfb3 Cysltr2 Phlpp1 Tnip3 Selp Cd27 
Sesn3 Xdh Tgfb2 Il20ra Ecm1 Sfrp4 Prnp Hgf Il18r1 Bcl6 
Fzd10 Cd24a Gcnt2 Fam110c Ntrk3 Itgb3 Sla2 Hes5 
Abca1 Dcc Tdgf1 Agpat9 Rasa3 Grm1 Rasa3 Dusp7 
Ntrk3 Pde4d Tnfaip3 Ntrk3 Fgfr1 C1qtnf3 Dusp5 Rora 
Il18r1 Adra1b P2rx4 Sipa1l1 Klf4 Sipa1l2 Wwc1 Sipa1l2 
Rasgrp2 Cyth3 Cat Cmya5 Dmd Akap7 Tgfb2 Pde4d 


















06 0.0213073 1.67E+00 
Klf2 Hc Slc46a2 Il7r Tnip3 Ptprz1 Selp Cd27 Lat2 Ccr2 
Epas1 Tgfb2 Procr Tspan2 Foxj1 Sptb Il18r1 Bcl6 Gcnt1 
Gpc3 Cxcl3 Cd24a Tcf7 Pde4b Ms4a1 S1pr1 Sla2 Tlx1 
Cxcr4 Ifnlr1 Txk P2ry14 Pigr Tdgf1 Slc8a3 Ctse Ptprz1 
Cd300lf Cx3cr1 Pde4d Fasl Myb Samhd1 Tspan2 Gab3 
Efna2 Tnfaip3 Cx3cr1 Rora Pglyrp1 Gcnt1 Ifitm1 Il18r1 
Foxp1 Pde4b Tcf7 Eml1 Spib Klf4 Serpinb9 Eml1 Ifitm1 
Aicda Eomes Cfh Ifnar1 Ifnar1 Pde4b Tgfb2 Pde4d Cblb 






06 0.0213073 1.67E+00 
Il7r Ccr2 Il1r2 Il18r1 Il18rap Cxcr4 Ifnlr1 Cxcr6 Il12rb2 


















06 0.0339258 1.47E+00 
Cacna1s Rapgef3 Tgfb3 Klf2 Serpinb5 Il7r Ptprz1 Selp 
Ptprb Ccr2 Epas1 Nyap2 mod1 Tgfb2 Ecm1 Foxj1 Sfrp4 
Spaca1 Matn2 Hgf Col4a2 Bcl6 Ramp1 Vcl Gcnt1 Map2 
Gpc3 Sema4f Tcf7 Ablim1 Nr4a2 S1pr1 Itgb3 Tlx1 Cxcr4 
Murc Dcc Tdgf1 Atp2b2 Spaca1 Sall3 Gcm1 Ptprz1 Nr2e1 
Cryaa Tead1 Wwox Fasl Cap2 Efna2 Fgfr1 Tbx6 Dusp5 
Rora Gcnt1 Ifitm1 Hmx2 Foxp1 Adora2a Tcf7 Ctnnd2 
Tmem106b Smo Klf4 Slitrk4 Ermn Flrt3 Ifitm1 Gcm1 







06 0.0339258 1.47E+00 




















06 0.0371204 1.43E+00 
Dusp10 Rapgef3 Tgfb3 Cysltr2 Cd59a Klf2 Hc Slc46a2 Il7r 
Ptprz1 Selp Lama4 Cd27 Ccr2 Epas1 Aspa Lag3 Sytl2 
Proc Xdh Tgfb2 Il20ra Procr Ecm1 Foxj1 Sfrp4 Prnp Hgf 
Col4a2 Il18r1 Tg Bcl6 Gpc3 Sema4f Cd24a Gcnt2 Pde4b 
Nr4a2 Ntrk3 S1pr1 Itgb3 Cxcr4 Hes5 Txk Dcc Tdgf1 
Il12rb2 Grm1 Ptprz1 Scn3b Nr2e1 Mfap4 Ntrk3 Cx3cr1 
Pde4d Fasl Myb Tnfaip3 Fgfr1 Sgip1 Tbx6 C1qtnf3 Rora 
Pglyrp1 Tnnt3 Adra1b P2rx4 Foxp1 Pde4b Adora2a 
Sipa1l1 Smo Klf4 Cmya5 Ntn1 Dmd Btg1 Eomes Kcnma1 







06 0.0372139 1.43E+00 
Tgfb3 Il7r Wisp1 Cd27 Lat2 Ccr2 Lag3 Clnk Tgfb2 Il20ra 
Sfrp4 Il1r2 Hgf Il18r1 Fzd10 Cd24a Tcf7 Gcnt2 Pde4b 
Ntrk3 Il18rap Itgb3 Cxcr4 Ifnlr1 Hes5 Abca1 Plaur Txk 
P2ry14 Pigr Dcc Cxcr6 Tdgf1 Adamts14 Il12rb2 Grm1 
Gria4 Adam34 Ntrk3 Cx3cr1 Wwox Fasl Kremen1 Efna2 
Cx3cr1 Ntrk3 Fgfr1 Vipr1 Tle2 P2rx4 Pde4b Adora2a Tcf7 
Sipa1l1 Smo Wisp1 Eya2 Gpr114 Cxcr6 Akap7 Ifnar1 


















05 0.0389147 1.41E+00 
Dusp10 Rapgef3 Tgfb3 Cysltr2 Cd59a Hc Phlpp1 Il7r 
Tnip3 Abcb9 Selp Cd27 Lat2 Ccr2 Sesn3 Lag3 Proc Xdh 
Tgfb2 Il20ra Grb7 Foxj1 Sfrp4 Prnp Hgf Il18r1 Bcl6 Ramp1 
Fzd10 Gpc3 Cd24a Gcnt2 Pde4b Fam110c Ntrk3 S1pr1 
Itgb3 Sla2 Nt5e Cxcr4 Ifnlr1 Hes5 Abca1 Txk Ramp3 Pigr 
Dcc Tdgf1 Agpat9 Rasa3 Bicc1 Sall3 Grm1 Dusp7 Cx3cr1 
Sell Pde4d Wwox Fasl Myb Samhd1 Tnfaip3 Fgfr1 
Zfyve28 C1qtnf3 Dusp5 Padi2 Rora Pglyrp1 Tle2 Adra1b 
Ramp3 P2rx4 Adora2a Sipa1l1 Klf4 Sipa1l2 Wwc1 
Rasgrp2 Cyth3 Cat Cmya5 Dmd Akap7 Cfh Pde4d Cblb 
Runx2 Ecm1 Igf1r Ccnd1 Kctd12 Tlr4 
GO:0098552 side of 
membrane 
1.38E-
05 0.0486405 1.31E+00 
Cd59a Il7r Selp Cd27 Ccr2 Lag3 Cd24a Klrc1 Ms4a1 
S1pr1 Itgb3 Cxcr4 Abca1 Rasa3 Il12rb2 Klra4 Klra1 Klrc1 














SUPPLEMENTARY FIGURES LEGENDS 1 
Figure E1. Effects of COX inhibitors on Il23r expression. (A) Expression of Il23r in 2 
differentiated Th17 cells treated with IL-23 (10 ng/ml) and/or PGE2 (100 nM) in the 3 
absence or presence of a COX-1 inhibitor, SC-560 (100 µM) or a COX-2 inhibitor, 4 
SC-236 (100 µM) or both for 3 days. (B) Th17 cells were cultured with vehicle, IL-23 5 
(10 ng/ml) and PGE2 (100 nM) or IL-23 (10 ng/ml), EP2 agonist (100 nM) and EP4 6 
agonist (100 nM) in the absence or presence of indomethacin (100 µM) for 3 days, and 7 
then harvested to analyze for Il23r expression by qRT-PCR. 8 
 9 
Figure E2. db-cAMP activates JAK2 and STAT3 in Th17 cells. (A) Time-course of 10 
STAT3 Y705 phosphorylation by vehicle, db-cAMP, IL-23 or db-cAMP and IL-23 in 11 
Th17 cells. Th17 cells were treated with IL-23 (10 ng/ml) for 3 days to induce IL-23R 12 
expression. The cells were then stimulated with either 100 µM db-cAMP or 100 ng/ml 13 
IL-23 or in combination for indicated times. Phosphorylation of STAT3 at Y705 14 
residues and S727 residues under each condition was examined at indicated times by 15 













of STAT3, total STAT3 and α-Tubulin. Representative images are shown (n=2). (B) 17 
Involvement of Src family kinase in cAMP-induced JAK2 Y1007/Y1008 18 
phosphorylation. Th17 cells were stimulated with 100 µM db-cAMP for 10 min in the 19 
presence of a Src inhibitor, Src Kinase Inhibitor I (10 µM), and subjected to Western 20 
blot analysis. Data was from a single experiment. 21 
 22 
Figure E3. Heat-map and gene ontology analysis of genes in each cluster. (A) Gene 23 
expression profiles in Th17 cells stimulated with db-cAMP and/or IL-23 followed by 24 
microarray analysis. Heat-map analysis of expression of genes 2-folds up- or 25 
down-regulated upon each stimulus compared to the vehicle control (One-way ANOVA 26 
p<0.05, n=3). (B) Gene ontology analysis of each clusters by GeneSpring.  27 
 28 
Figure E4. Involvement of PGE2 signaling in psoriasis-like model. (A) Gene 29 
expression of PGE2 synthases in ear skin from naïve WT mice or psoriasis-like skin 30 
lesions from mice administrated with IL-23 by intradermal injection in the dorsum (n=5 31 













Genetic loss of Ptger2 (EP2 KO) or pharmacological EP4 antagonism alone does not 33 
cause alteration in the ear. Psoriasis-like model in WT and EP2 KO mice were 34 
established as described in Figure 5A. Ear swelling was measured every 2 days (B) 35 
(n=14, 10, 8, and 10 in vehicle-treated mice, EP2 KO mice, AS1954813-treated WT 36 
mice, AS1954813-treated EP2 KO mice, respectively) and ear skins were subjected to 37 
FACS analysis on day 4 (C). (D and E) Suppression of IL-17A+ and IL-17A+IFN-γ+ 38 
CD4+ T cell accumulation by EP2 KO and EP4 antagonist. WT and EP2 KO mice were 39 
administered either vehicle or AS1954813, and subcutaneously injected IL-23. CD4+ T 40 
cells were purified from the ear of each group on day 4 and examined by FACS for 41 
IL-17A and IFN-γ. Representative data from 4 independent experiments are shown. All 42 
bars indicate mean ± SEM. *, p<0.05, **, p<0.01, ***, p<0.001. 43 
 44 
Figure E5. FACS analysis of cell populations of EP2fl/flEP4fl/flLck-Cre+ mice or WT 45 
Lck-Cre+ mice. (A) Cell population of EP2fl/flEP4fl/flLck-Cre+ mice and control WT 46 
Lck-Cre+ mice. The numbers of B cell, T cell, CD4 T cell, CD8 T cell, Th1 cell, Th17 47 













analyzed by FACS. (n=3-4) 49 
 50 
Figure E6. Involvement of PGE2 signaling in IMQ-induced psoriasis-like model and 51 
the effect of COX inhibitors on IL-23-induced psoriasis model. (A) Control WT 52 
mice and Ptger2-deficient (EP2 KO) mice were subjected to imiquimod (IMQ)-induced 53 
psoriasis model and administered either vehicle or AS1954813, 100 mg/kg, as described 54 
in Figure 5A. Ear swelling was measured every 2 days (A) (n=14, 10, 8, and 10 in 55 
vehicle-treated mice, EP2 KO mice, AS1954813-treated WT mice, AS1954813-treated 56 
EP2 KO mice, respectively). (B-D) Female WT mice were subjected to IL23-induced 57 
psoriasis model and administered either vehicle, SC-236 (10mg/kg) or indomethacin (4 58 
mg/kg). Ear swelling was measured every 2 days (B) (n=4, respectively) and mice were 59 
sacrificed and subjected to FACS analysis at day 4 (C and D). 60 
 61 
Figure E7. IL-1β-IL1 receptor signaling was not involved in Il23r expression by 62 
Th17 cells. Expression of Il23r gene in differentiated Th17 cells stimulated with 63 













various concentrations of neutralization antibody for IL-1β for 3 days was analyzed by 65 
qRT-PCR (n=3). All bars indicate mean ± SEM.  66 
 67 
Table E 1. List of genes in Cluster 1U. 68 
 69 
Table E 2. List of genes in Cluster 2U. 70 
 71 
Table E 3. List of genes in Cluster 3U. 72 
 73 
Table E 4. List of genes in Cluster 4U. 74 
 75 
Table E 5. List of genes in Cluster 1D.  76 
 77 
Table E 6. List of genes in Cluster 2D. 78 
 79 














Table E 8. List of genes in Cluster 4D. 82 
 83 
Table E 9. List of gene ontology from Cluster 1U. 84 
 85 
Table E 10. List of gene ontology from Cluster 2U. 86 
 87 
Table E 11. List of gene ontology from Cluster 3U. 88 
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